0001213900-22-011208 | 10-K | XBRL Viewer

Print Document View Excel Document

Consolidated Balance Sheets - USD ($) $ in Thousands	Dec. 31, 2021	Dec. 31, 2020
Current assets:
Cash and cash equivalents	$ 35,724	$ 168,598
Restricted cash		50
Marketable debt securities	55,505
Prepaid expenses and other current assets	1,883	787
Total current assets	93,112	169,435
Restricted cash, non-current	745	745
Marketable debt securities, non-current	39,467
Property and equipment, net	1,719	1,240
Operating lease right-of-use asset	7,171	1,060
Goodwill	29,517	29,517
Other assets	865	1,160
Total assets	172,596	203,157
Current liabilities:
Accounts payable	954	914
Accrued expenses	2,489	1,913
Operating lease liability	855	88
Total current liabilities	4,298	2,915
Operating lease liability, non-current	6,384	999
Total liabilities	10,682	3,914
Commitments and contingencies (Note 11)
Preferred stock, $0.001 par value, authorized 10,000,000 shares:
Preferred stock, $0.001 par value, authorized 10,000,000 shares, Series 1 convertible preferred stock, 8,028 shares authorized at December 31, 2021 and 2020, respectively 8,027 shares issued and outstanding as of December 31, 2021 and 2020, respectively.
Common stock, $0.001 par value, authorized 100,000,000 shares:
Common stock, $0.001 par value, authorized 100,000,000 shares, Common stock, 11,235,731 and 11,211,840 shares issued and outstanding as of December 31, 2021 and 2020, respectively.	11	11
Additional paid in capital	256,126	245,992
Accumulated deficit	(94,012)	(46,760)
Accumulated other comprehensive income (loss)	(211)
Total stockholders’ equity	161,914	199,243
Total liabilities and stockholders’ equity	$ 172,596	$ 203,157

Consolidated Balance Sheets (Parentheticals) - $ / shares	Dec. 31, 2021	Dec. 31, 2020
Preferred stock, par value (in Dollars per share)	$ 0.001	$ 0.001
Preferred stock, shares authorized	10,000,000	10,000,000
Common stock, par value (in Dollars per share)	$ 0.001	$ 0.001
Common stock, shares authorized	100,000,000	100,000,000
Common stock, shares issued	11,235,731	11,211,840
Common stock, shares outstanding	11,235,731	11,211,840
Series 1 Convertible Preferred Stock
Preferred stock, shares authorized	8,028	8,028
Preferred stock, shares issued	8,027	8,027
Preferred stock, shares outstanding	8,027	8,027

Consolidated Statements of Operations and Comprehensive Loss - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Operating expenses:
Research and development	$ 21,088	$ 11,982
General and administrative	26,401	22,462
Total operating expenses	47,489	34,444
Loss from operations	(47,489)	(34,444)
Other income (expense), net
Interest and investment income	237	500
Interest expense		(34)
Other income (expense), net	237	466
Net loss	$ (47,252)	$ (33,978)
Net loss per share attributable to common stockholders, basic and diluted (in Dollars per share)	$ (4.21)	$ (4.7)
Weighted average shares outstanding, basic and diluted (in Shares)	11,232,576	7,233,913
Other comprehensive income (loss):
Net unrealized (loss) gain on marketable debt securities	$ (211)
Other comprehensive income (loss)	(211)
Comprehensive Loss	$ (47,463)	$ (33,978)

Consolidated Statements of Changes in Stockholders’ Equity - USD ($) $ in Thousands	Series 1 Convertible Preferred Stock	Common Stock	Additional Paid-in Capital	Accumulated Deficit	Accumulated Other Comprehensive Loss	Total
Balance at Dec. 31, 2019		$ 3	$ 10,651	$ (12,782)		$ (2,128)
Balance (in Shares) at Dec. 31, 2019		2,627,533
Issuance of Common Stock in ArTara Private Placement, net of offering costs			1,867			1,867
Issuance of Common Stock in ArTara Private Placement, net of offering costs (in Shares)		284,875
Issuance of Common Stock in Proteon Private Placement, net of offering costs		$ 2	12,411			12,413
Issuance of Common Stock in Proteon Private Placement, net of offering costs (in Shares)		1,896,888
Issuance of Series 1 Convertible Preferred Stock in Proteon Private Placement, net of offering costs			25,319			25,319
Issuance of Series 1 Convertible Preferred Stock in Proteon Private Placement, net of offering costs (in Shares)	3,879
Reverse business combination		$ 1	34,532			34,533
Reverse business combination (in Shares)		1,033,907
Issuance of Common Stock in public offering, net of offering costs		$ 4	73,566			73,570
Issuance of Common Stock in public offering, net of offering costs (in Shares)		4,600,000
Issuance of Series 1 Convertible Preferred in public offering, net of offering costs			66,284			66,284
Issuance of Series 1 Convertible Preferred in public offering, net of offering costs (in Shares)	4,148
Issuance of Common Stock in Common Offering (Underwriters Overallotment Option), net of offering costs		$ 1	11,086			11,087
Issuance of Common Stock in Common Offering (Underwriters Overallotment Option), net of offering costs (in Shares)		690,000
Settlement of restricted stock units
Settlement of restricted stock units (in Shares)		20,870
Exercise of stock options			530			530
Exercise of stock options (in Shares)		57,767
Stock-based compensation expense			9,746			9,746
Stock-based compensation expense (in Shares)
Net loss				(33,978)		(33,978)
Balance at Dec. 31, 2020		$ 11	245,992	(46,760)		199,243
Balance (in Shares) at Dec. 31, 2020	8,027	11,211,840
Settlement of restricted stock units			(228)			(228)
Settlement of restricted stock units (in Shares)		23,891
Stock-based compensation expense			10,362			10,362
Stock-based compensation expense (in Shares)
Other comprehensive loss					(211)	(211)
Other comprehensive loss (in Shares)
Net loss				(47,252)		(47,252)
Balance at Dec. 31, 2021		$ 11	$ 256,126	$ (94,012)	$ (211)	$ 161,914
Balance (in Shares) at Dec. 31, 2021	8,027	11,235,731

Consolidated Statements of Cash Flows - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Cash flows from operating activities:
Net loss	$ (47,252)	$ (33,978)
Adjustments to reconcile net loss to net cash used in operating activities:
Stock based compensation	10,362	9,746
Operating lease right-of-use asset	1,050	93
Depreciation	117	103
Amortization of premium on marketable debt securities	1,737
Changes in operating assets and liabilities:
Prepaid expenses and other current assets	(418)	1,405
Other assets	295	58
Accounts payable	40	198
Accrued expenses	576	(966)
Operating lease liabilities	(1,009)	(66)
Net cash used in operating activities	(34,502)	(23,407)
Cash flows from investing activities:
Cash and restricted cash acquired in connection with the reverse merger with ArTara Therapeutics, Inc.		3,719
Purchase of marketable debt securities	(124,748)
Proceeds from maturity and redemption of marketable debt securities	27,150
Purchase of property and equipment	(596)	(884)
Net cash (used in)/provided by investing activities	(98,194)	2,835
Cash flows from financing activities:
Proceeds from - ArTara Private Placement, net of offering costs		1,867
Proceeds from - Common Stock in Proteon Private Placement, net of offering costs		12,413
Proceeds from - Series 1 Convertible Preferred Stock in Proteon Private Placement, net of offering costs		25,319
Proceeds from Common Offering, net of offering costs		73,570
Proceeds from Preferred Offering, net of offering costs		66,284
Proceeds from Underwriters Overallotment Option		11,087
Repayments under short-term debt		(1,669)
Proceeds from the exercise of stock options		530
Repurchase of shares in connection with settlement of RSUs	(228)
Net cash (used in)/provided by financing activities	(228)	189,401
Net (decrease)/increase in cash and cash equivalents and restricted cash	(132,924)	168,829
Cash and cash equivalents and restricted cash - beginning of year	169,393	564
Cash and cash equivalents and restricted cash - end of period	36,469	169,393
Cash paid for:
Interest		34
Income Taxes
Supplemental schedule of non-cash activities:
Deferred offering costs recognized that were previously recorded in accrued expenses		122
Purchase of insurance agreement with notes payable		1,669
Common stock issued in connection with the reverse merger with ArTara Therapeutics, Inc.		$ 34,533

Organization and Nature of the Business

12 Months Ended

Dec. 31, 2021

Accounting Policies [Abstract]

Organization and Nature of the Business

1. Organization and Nature of the Business

Overview

Protara Therapeutics, Inc., and its consolidated subsidiaries (“Protara” or the “Company”), is a clinical-stage biopharmaceutical company committed to identifying and advancing transformative therapies for the treatment of cancer and rare diseases with significant unmet needs. Protara’s portfolio includes two development programs utilizing TARA-002, an investigational cell therapy in development for the treatment of lymphatic malformations (“LMs”) and non-muscle invasive bladder cancer (“NMIBC”). The third program in the portfolio is Intravenous (“IV”) Choline Chloride, an investigational phospholipid substrate replacement therapy initially in development for patients receiving parenteral nutrition (“PN”) who have intestinal failure associated liver disease (“IFALD”).

On January 9, 2020, privately-held ArTara Subsidiary, Inc. (“Private ArTara”) and Protara Therapeutics, Inc. (formerly ArTara Therapeutics, Inc., formerly Proteon Therapeutics, Inc.) completed the merger and reorganization (the “Merger”), in accordance with the terms of the Agreement and Plan of Merger and Reorganization, dated September 23, 2019, (the “Merger Agreement”) by and among Protara Therapeutics, Inc., Private ArTara and REM 1 Acquisition, Inc., a wholly owned subsidiary of Protara Therapeutics, Inc (“Merger Sub”). Thereupon, Merger Sub merged with and into Private ArTara, with Private ArTara surviving as a wholly owned subsidiary of Protara Therapeutics, Inc. The Merger was structured as a reverse merger and Private ArTara was determined to be the accounting acquirer based on the terms of the Merger and other factors, and the post-merger company retained the name ArTara Therapeutics, Inc., which on May 11, 2020 was changed to Protara Therapeutics, Inc.

On January 9, 2020, in connection with and prior to the completion of the Merger, Protara Therapeutics, Inc. effected a 1-for-40 reverse stock split of its common stock (the “Protara Reverse Stock Split”), Private ArTara changed its name from “ArTara Therapeutics, Inc.” to “ArTara Subsidiary, Inc.”, and ArTara Therapeutics, Inc. changed its name from “Proteon Therapeutics, Inc.” to “ArTara Therapeutics, Inc” then subsequently changed its name from “ArTara Therapeutics, Inc” to “Protara Therapeutics, Inc.” All share and per share amounts presented in this Annual Report on Form 10-K have been adjusted to reflect the Protara Reverse Stock Split and the Exchange Ratio (defined below). In addition, immediately following the closing of the Private Placements (defined below), all of the outstanding shares of Protara Therapeutics, Inc.’s Series A Preferred Stock were converted into shares of Protara Therapeutics, Inc.’s common stock. Shares of the Company’s common stock commenced trading on The Nasdaq Capital Market under the new name and ticker symbol “TARA” as of market open on January 10, 2020. See Note 3 for the full discussion regarding the Merger, Exchange Ratio and recapitalization

Liquidity, Capital Resources and Management Plans

The Company is in the business of developing biopharmaceuticals and has no current or near-term revenues. The Company has incurred substantial clinical and other costs in its drug development efforts. The Company will need to raise additional capital in order to fully realize management’s plans.

The Company believes that its current financial resources are sufficient to satisfy the Company’s estimated liquidity needs for at least twelve months from the date of issuance of these consolidated financial statements.

Impact of COVID-19

The ultimate impact of the current COVID-19 pandemic is highly uncertain and subject to change. The Company has experienced delays and may experience additional future delays that impact the business, research and development activities, the healthcare systems in which the Company operates and the global economy as a whole. Due to the continued evolution of the COVID-19 pandemic and the global responses to curb its spread, the Company is not able to estimate the ongoing effects on the Company’s results of operations, financial condition, or liquidity. The Company will continue to monitor the COVID-19 public health crisis closely including whether the effects would have a material impact on the Company’s operations, liquidity and capital resources

Summary of Significant Accounting Policies

12 Months Ended

Dec. 31, 2021

Accounting Policies [Abstract]

Summary of Significant Accounting Policies

2. Summary of Significant Accounting Policies

Basis of Presentation

The accompanying consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (“U.S. GAAP” or “GAAP”).

Principles of Consolidation

The consolidated financial statements include the accounts of the Company and its wholly owned subsidiaries. All intercompany balances and transactions have been eliminated in the accompanying consolidated financial statements.

Use of Estimates

The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, revenues, expenses, and related disclosure of contingent assets and liabilities at the date of the consolidated financial statements. Significant items subject to such estimates include but are not limited to income taxes, the valuation of deferred tax assets, recoverability of goodwill, and contingencies.

On an ongoing basis, the Company’s management evaluates its estimates based on historical and anticipated results, trends, and various other assumptions believed to be reasonable. Actual results could differ from those estimates. The results of any changes in accounting estimates are reflected in the financial statements of the period in which the change becomes evident.

Reclassification

Certain amounts in prior periods related to the classification of operating right-of-use assets have been reclassified to conform to current period presentation. These reclassifications to adjust prior period presentation had no impact on consolidated statements of operations and comprehensive loss or consolidated statements of cash flows.

Business Combinations

The purchase price of the assets acquired and the liabilities assumed are measured at their fair values and recognized at the acquisition date, including identifiable intangible assets that either arise from a contractual or legal right or are separable from goodwill. The excess purchase price over the value of net tangible and identifiable intangible assets acquired is recorded as goodwill.

Deferred tax liabilities and assets are recognized for the deferred tax consequences of differences between the tax bases and the recognized values of assets acquired and liabilities assumed in a business combination. See Note 3 for the Company’s accounting for the reverse merger.

Cash, Cash Equivalents and Restricted Cash

The Company considers all highly liquid instruments with an original maturity of three months or less when acquired to be cash equivalents. Cash and cash equivalents are held in depository and money market accounts and are reported at fair value. The Company’s restricted cash balances consist of cash deposits to collateralize letter of credit obligations.

The following table provides a reconciliation of cash, cash equivalents, and restricted cash in the consolidated balance sheets to the total amount shown in the consolidated statements of cash flows:

	December 31,
	2021		2020
Cash and cash equivalents	$	35,724	$	168,598
Restricted cash		-		50
Restricted cash, non-current		745		745
Total cash, cash equivalents and restricted cash shown in the consolidated statements of cash flows	$	36,469	$	169,393

Fair Value Measurements

Accounting Standards Codification (“ASC”) Topic 820 “Fair Value Measurements” provides the framework for measuring fair value and establishes a fair value hierarchy that prioritizes the inputs used in pricing the asset or liability. The hierarchy gives the highest priority to unadjusted quoted prices in active markets for identical assets or liabilities (level 1 measurements) and the lowest priority to unobservable inputs (level 3 measurements).

Fair value is defined as the exchange price, or an exit price, representing the amount that would be received upon the sale of an asset or payment to transfer a liability in an orderly transaction between market participants. As a basis for considering market participant assumptions in fair value measurements, the three-tier fair value hierarchy is used to prioritize the inputs in measuring fair value as follows:

	Ø	Level 1 Quoted prices in active markets for identical assets or liabilities.

	Ø	Level 2 Quoted prices for similar assets or liabilities in active markets, quoted prices for identical or similar assets or liabilities in markets that are not active, or other inputs that are observable, either directly or indirectly.

Level 3 Significant unobservable inputs that cannot be corroborated by market data.

The carrying amounts of cash and cash equivalents, prepaid expenses and accounts payable approximate their fair values due to the short-term nature of these instruments.

Marketable Debt Securities

The Company classifies investments in marketable debt securities with remaining maturities when purchased of greater than three months as available-for-sale. Investments with a remaining maturity date greater than one year are classified as non-current. The cost of securities sold is based on the specific identification method. Interest and dividends on securities classified as available-for-sale are included in investment income.

The Company records investments at fair value with unrealized gains and losses recorded as a component of other comprehensive loss in the consolidated statements of operations and comprehensive loss until realized. Fair value is determined based on quoted market rates when observable or utilizing data points that are observable, such as quoted prices, interest rates and yield curves. To determine whether an other-than-temporary impairment exists, the Company considers whether it has the ability and intent to hold the investment until a market price recovery, and whether evidence indicating the recoverability of the cost of the investment outweighs evidence to the contrary. The Company has the ability to hold such securities with an unrealized loss until its forecasted recovery. The Company determined that there was no material change in the credit risk of these investments.

Concentrations of Credit Risk

Financial instruments that potentially subject the Company to concentrations of credit risk include amounts held as cash, cash equivalents, restricted cash, and marketable debt securities. The Company uses high quality, accredited financial institutions to maintain its balances, and accordingly, such funds are subject to minimal credit risk. The Company has not experienced any losses in such accounts and management believes that the Company is not exposed to significant credit risk due to the financial position of the depository institutions in which those deposits are held. The Company has no financial instruments with off-balance sheet risk of loss.

Property and Equipment, net

Property and equipment, including leasehold improvements, are recorded at cost less accumulated depreciation and amortization. Depreciation is computed using the straight-line method over the estimated useful life of the asset. Depreciation begins at the time the asset is placed in service. Leasehold improvements are amortized using the straight-line method over the shorter of the lease term or estimated useful life of the asset. Repairs and maintenance costs are expensed as incurred, whereas major improvements are capitalized as additions to property and equipment.

The estimated useful lives for significant property and equipment categories are as follows:

Asset Classification		Estimated Useful Life
Computer equipment		5
Furniture, fixtures and other		5
Laboratory equipment		7
Leasehold improvements		Shorter of the useful life of asset or the lease term

Impairment of Long-Lived Assets

Long-lived assets are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of the asset or asset group may not be recoverable or that the useful life is shorter than originally estimated. When such events occur, the Company compares the carrying amounts of the asset or asset group to the undiscounted expected future cash flows. If this comparison indicates that the asset or asset group is impaired, the amount of impairment is measured as the difference between the carrying value and fair value of the asset or asset group. If the useful life is shorter than originally estimated, the Company will amortize the remaining carrying value over the new shorter useful life. To date, no such impairment loss has been recognized.

Leases

The Company enters into contracts in the normal course of business and assesses whether any such contracts contain a lease. The Company determines if an arrangement is a lease at inception if it conveys the right to control the identified asset for a period of time in exchange for consideration. Under ASC 842, lease expense is recognized as a single lease cost on a straight-line basis over the lease term. The lease term consists of non-cancelable periods and may include options to extend or terminate the lease term, when it is reasonably certain such options will be exercised.

Leases classified as operating leases are included in operating lease right-of-use (“ROU”) assets, current operating lease liabilities and noncurrent operating lease liabilities in our consolidated balance sheet. Finance leases are included in property and equipment and finance lease obligations, in our consolidated balance sheet. ROU assets represent the right to use an underlying asset for the lease term. Lease liabilities represent the present value of future lease payments, net of lease incentives, discounted using an incremental borrowing rate, which is a management estimate based on the information available at the commencement date of a lease arrangement. ROU assets and lease liabilities are recognized at the lease commencement date.

The Company has elected to account for the lease and non-lease components for leases as a single component for classes of all underlying assets and allocate all the contract consideration to the lease component only. Lease cost for operating leases is recognized on a straight-line basis over the lease term and is included in operating expenses on the statements of operations and comprehensive loss. Variable lease payments are included in lease operating expenses.

The Company recognizes costs associated with lease arrangements having an initial term of 12 months or less (“short-term leases”) on a straight-line basis over the lease term; such short-term leases are not recorded on the balance sheet.

Segment Information

The Company identifies its operating segments in accordance with Accounting Standards Codification (“ASC”) 280, Segment Reporting (“ASC 280”). Operating segments are defined as components of an enterprise about which separate discrete financial information is available for evaluation by the chief operating decision maker, or decision-making group, in deciding how to allocate resources and in assessing performance. The Company’s chief operating decision maker, its Chief Executive Officer, manages the Company’s operations on a consolidated basis for the purposes of allocating resources. Accordingly, the Company has determined it operates and manages its business in a single reportable operating segment.

Goodwill

On January 9, 2020, in connection with the Merger, the Company separately valued the assets and liabilities acquired, and then determined goodwill as the residual of the purchase price less identified net assets. The carrying value of goodwill is $29.5 million at December 31, 2021 and 2020, respectively.

Goodwill represents the excess of purchase price over the fair value of identifiable net assets acquired in a business combination. Goodwill has an indefinite useful life. Goodwill is assessed annually for impairment as of December 31, or more frequently if an event occurs or circumstances change that would indicate that it is more likely than not that the fair value of a reporting unit or the fair value of an indefinite-lived intangible asset has declined below its carrying value. In performing its annual goodwill impairment assessment, the Company has the option under GAAP to qualitatively assess whether it is more likely than not that the fair value of a reporting unit is less than its carrying value; if the conclusion of the qualitative assessment is that there are no indicators of impairment, the Company does not perform a quantitative assessment. Otherwise, a quantitative assessment is performed and the fair value of the reporting unit is determined.

Goodwill is evaluated for impairment at the reporting unit level, which is defined as an operating segment, or one level below an operating segment. The Company has determined that it operates as one reporting unit and has selected December 31 as the date to perform its annual impairment test.

As of December 31, 2021, the Company elected to forego the qualitative screen and performed a quantitative annual goodwill impairment test for the reporting unit. As of December 31, 2020, the Company elected to perform a qualitative impairment assessment of goodwill impairment and considered qualitative indicators of the fair value of the reporting unit. Based upon the results of our annual goodwill impairment test, no adjustments to the carrying value of goodwill were necessary during the years ended December 31, 2021 and 2020.

Research and Development

Research and development expenses consist primarily of third-party costs incurred to develop drug candidates, employee-related expenses, including salaries, benefits, travel and stock-based compensation expense, depreciation and other allocated overhead costs, which include rent and maintenance of facilities and other supplies. Research and development costs are expensed as incurred.

Before a compound receives regulatory approval, the Company records upfront and milestone payments made to third parties under licensing arrangements as expense provided that there is no alternative future use of the rights in other research and development projects.

Nonrefundable advance payments to vendors for goods or services that will be used or received in future research and development activities are deferred and recognized as expense in the period in which the related goods are delivered or services are performed. Where milestone payments are due to third parties under research and development collaboration arrangements or other contractual agreements, the milestone payment obligations are expensed when the milestone conditions are met and the amount of payment is reasonably estimable.

Once a compound receives regulatory approval, the Company records any milestone payments in identifiable intangible assets, less accumulated amortization and, unless the asset is determined to have an indefinite life, the Company amortizes the payments on a straight-line basis over the remaining agreement term or the expected product life cycle, whichever is shorter.

Certain third-party costs are included as a component of research and development expense. These expenses include fees paid to contract research organizations (“CROs”) and other clinical trial costs, contractual services costs and costs for supply of its drug candidates. Depending upon the timing of payments to the service providers, the Company recognizes prepaid expenses or accrued expenses related to these costs. These accrued or prepaid expenses are based on management’s estimates of the work performed under service agreements, milestones achieved and experience with similar contracts. The Company monitors each of these factors and adjusts estimates accordingly.

Patent Costs

All patent-related costs incurred in connection with filing and prosecuting patent applications are expensed as incurred due to the uncertainty about the recovery of the expenditure. Amounts incurred are classified as general and administrative expenses.

Investment Income

Investment income consists primarily of interest income and accretion income earned and amortization expense incurred related to our marketable debt securities and interest income related to cash, cash equivalents and restricted cash.

Stock-Based Compensation

The Company’s stock-based compensation programs include stock options, restricted stock units (“RSUs”), and an employee stock purchase program (“ESPP”). The Company accounts for stock-based compensation using the fair value method.

The Company measures all stock options and other stock-based awards granted to employees and directors based on the fair value on the date of the grant and recognizes compensation expense of those awards over the requisite service period, which is generally the vesting period of the respective award. The Company recognizes forfeitures at the time forfeitures occur.

The fair value of each option is estimated on the date of grant using the Black-Scholes option-pricing model. Expected volatility for the Company’s common stock is determined based on an average of the historical volatility of the Company and the historical volatility of a peer-group of similar public companies. The expected term of options granted to employees is calculated using the simplified method, which represents the average of the contractual term of the option and the weighted-average vesting period of the option. The assumed dividend yield is based upon the Company’s expectation of not paying dividends in the foreseeable future. The risk-free interest rate is based upon the U.S. Treasury yield curve commensurate with the expected term at the time of grant or remeasurement.

The stock-based compensation expense associated with purchase rights under the ESPP is measured at fair-value using a Black-Scholes option-pricing model at commencement of each offering period and recognized over that offering period. The Black-Scholes option pricing assumptions are similar to those used for stock options with the exception of the expected term of purchase rights for the ESPP which is based on the duration of an offering period.

The fair values of RSUs are based on the fair market value of the Company’s common stock on the date of the grant.

The RSUs are granted to directors pursuant to the Company’s equity plan. Settlement for the RSUs is deferred until the earliest to occur of (i) the director’s termination of service, (ii) death, (iii) disability or (iv) a change in control of the Company. In the event of a change in control of the Company, the RSUs will vest in full.

The fair value of all stock-based awards is recognized as stock-based compensation expense on a straight-line basis over the vesting period, which is typically one to four years for RSUs and four years for stock options.

The Company classifies stock-based compensation expense in its statement of operations and comprehensive loss in the same way the payroll costs or service payments are classified for the related stock-based award recipients.

Income Taxes

Deferred tax assets and liabilities are recognized for the estimated future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax basis, operating loss and tax credit carryforwards. Deferred tax assets and liabilities are measured using enacted tax rates in effect for the year in which those temporary differences are expected to be recovered or settled. The measurement of net deferred tax assets is reduced by the amount of any tax benefit that, based on available evidence, is not expected to be realized, and a corresponding valuation allowance is established. In making such a determination, the Company considers all available positive and negative evidence, including future reversals of existing taxable temporary differences, projected future taxable income, tax-planning strategies, and results of recent operations.

Tax benefits are recognized only for tax positions that are more likely than not to be sustained upon examination by tax authorities. The amount recognized is measured as the largest amount of benefit that is greater than 50 percent likely to be realized upon settlement. A liability for unrecognized tax benefits is recorded for any tax benefits claimed in the Company’s tax returns that do not meet these recognition and measurement standards. The Company’s policy is to record interest and penalties on uncertain tax positions as a component of income tax expense in the consolidated statement of operations and comprehensive loss.

Net Loss Per Share Attributable to Common Stockholders

Basic net loss per share is computed by dividing the net loss attributable to common stockholders by the weighted-average number of shares of common stock outstanding during the period. Diluted net loss per share is computed by dividing net loss attributable to common stockholders by the weighted-average number of shares of common stock outstanding during the period plus the common equivalent shares for the period including any dilutive effect from unvested restricted common stock, outstanding stock options and potential shares issuable under the ESPP.

Recently Adopted Accounting Pronouncements

In August 2018, the Financial Accounting Standards Board, or the FASB, issued ASU No. 2018-15, Intangibles – Goodwill and Other – Internal-Use Software (Subtopic 350-40): Customer’s Accounting for Implementation Costs Incurred in a Cloud Computing Arrangement That Is a Service Contract (“ASU 2018-15”). This ASU is designed to reduce complexity for accounting for costs of implementing a cloud computing service arrangement. This standard aligns the accounting for implementation costs of hosting arrangements, regardless of whether they convey a license to the hosted software. The standard became effective for the first interim period within annual reporting periods beginning after December 15, 2020. On January 1, 2021, the Company adopted ASU 2018-15. The adoption of this standard did not have a material effect on the Company’s financial position, results of operations, or cash flows.

In December 2019, the FASB issued ASU 2019-12, Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes (“ASU 2019-12”). The amendments in ASU 2019-12 remove certain exceptions to the general principles in Topic 740. The amendments also clarify and amend existing guidance to improve consistent application. The amendments became effective for annual reporting periods beginning after December 15, 2020. On January 1, 2021, the Company adopted ASU 2019-12. The adoption of this standard did not have a material effect on the Company’s financial position, results of operations, or cash flows.

Recent Accounting Pronouncements Not Yet Adopted

In June 2016, the FASB issued ASU 2016-13, Measurement of Credit Losses on Financial Statements (“ASU 2016-13”). The new standard requires that expected credit losses relating to financial assets measured on an amortized cost basis and available-for-sale debt securities be recorded through an allowance for credit losses. It also limits the amount of credit losses to be recognized for available-for-sale debt securities to the amount by which carrying value exceeds fair value and also requires the reversal of previously recognized credit losses if fair value increases. In November 2019, the FASB issued ASU 2019-10, Financial Instruments – Credit Losses (Topic 326), Derivatives and Hedging (Topic 815), and Leases (Topic 842): Effective Dates (ASU 2019-10), which amended the effective date for certain companies. The standard is effective for public companies eligible to be smaller reporting companies for annual and interim periods beginning after December 15, 2022. Early adoption is available. The Company is currently evaluating the potential impact ASU 2016-13, and related updates, will have on its consolidated financial statements and disclosures.

The Company has evaluated other recently issued accounting pronouncements and has concluded that the impact of recently issued standards that are not yet effective will not have a material impact on the Company’s financial position or results of operations upon adoption.

Subsequent Events

The Company evaluated subsequent events and transactions that occurred after the balance sheet date up to the date that the financial statements were available to be issued. Other than as described in Note 13, the Company did not identify any subsequent events that would have required adjustment or disclosure in the financial statements.

Reverse Merger with Protara and Recapitalization

12 Months Ended

Dec. 31, 2021

Reverse Merger with Protara and Recapitalization [Abstract]

Reverse Merger with Protara and Recapitalization

3. Reverse Merger with Protara and Recapitalization

On January 9, 2020, in connection with, and prior to the completion of the Merger, Protara Therapeutics, Inc. effected the Protara Reverse Stock Split, which resulted in 557,631 pre-merger shares of Protara Therapeutics, Inc. outstanding.

Under the terms of the Merger Agreement, Protara Therapeutics, Inc. issued shares of its common stock to the Company’s stockholders, at an exchange ratio of 0.190756 (the “Exchange Ratio”), after taking into account the Protara Reverse Stock Split, for each share of Private ArTara common stock outstanding immediately prior to the Merger. Protara Therapeutics, Inc. assumed all of the unvested Private ArTara restricted stock awards, which were exchanged for a number of shares of Protara Therapeutics, Inc.’s common stock equal to 0.190756 multiplied by the number of shares of Private ArTara common stock previously represented by such Private ArTara restricted stock awards and unvested to the same extent as such Private ArTara restricted stock awards and subject to the same restrictions as such Private ArTara restricted stock awards. On account of the adjustment required pursuant to the Exchange Ratio, there were 2,627,533 shares of Private ArTara common stock outstanding immediately prior to the Merger.

Protara Therapeutics, Inc. assumed all of the outstanding and unexercised stock options of Private ArTara, with such stock options representing the right to purchase a number of shares of Protara Therapeutics, Inc.’s common stock equal to 0.190756 multiplied by the number of shares of Private ArTara common stock previously represented by such Private ArTara stock options. As a result, 219,699 shares were assumed under Private ArTara’s 2017 Equity Incentive Plan. No additional awards will be made under the 2017 Equity Incentive Plan. On January 1, 2020, Protara Therapeutics, Inc. amended its Amended and Restated 2014 Equity Incentive Plan (the “Amended 2014 Plan”) to increase the number of shares of stock available for issuance under the 2014 Equity Incentive Plan to 1,048,300 shares and made conforming changes and updates pursuant to Section 162(m) of the Code.

Concurrently with the execution of the Merger Agreement, certain institutional investors (together, the “Investors”) entered into a subscription agreement (as amended on November 19, 2019, the “Subscription Agreement”) with Protara Therapeutics, Inc. and Private ArTara, pursuant to which (A) Protara Therapeutics, Inc. issued in a private placement immediately after the Merger (the “Proteon Private Placement”) (i) 3,879.356 of shares of Protara Therapeutics, Inc.’s Series 1 Convertible Non-Voting Preferred Stock at a purchase price of approximately $7,011.47 per share for gross proceeds of $27,200 and proceeds, net of issuance costs, of $25,319, (ii) 1,896,888 shares of Protara Therapeutics, Inc.’s common stock at a purchase price of approximately $7.01 per share for gross proceeds of $13,300 and proceeds, net of issuance costs, of $12,413 and (B) Private ArTara issued in a private placement immediately prior to the Merger (the “ArTara Private Placement”) 284,875 shares of Private ArTara common stock (post-Exchange Ratio basis) at a purchase price of approximately $7.01 per share (post-Exchange Ratio basis) (together with the Proteon Private Placement, the “Private Placements”) for gross proceeds of $2,000 and proceeds, net of issuance costs, of $1,867. The shares issued in the Proteon Private Placement were registered for resale on a registration statement on Form S-3 filed and declared effective by the SEC on January 30, 2020.

Immediately following the closing of the Proteon Private Placement, 18,954 shares of Protara Therapeutics, Inc.’s Series A Convertible Preferred Stock outstanding were converted into 476,276 shares of Protara Therapeutics, Inc.’s common stock. These shares, combined with the 557,631 pre-merger shares of Protara Therapeutics, Inc. outstanding after the Protara Reverse Stock Split, resulted in an aggregate of 1,033,907 shares of Protara Therapeutics, Inc.’s common stock issued in connection with the Merger.

Immediately after the consummation of the Merger and prior to the consummation of the Proteon Private Placement, the former stockholders and option holders of Private ArTara owned, or held rights to acquire, approximately 75.2% of the fully diluted common stock of Protara, with Protara Therapeutics, Inc.’s stockholders and option holders immediately prior to the Merger owning approximately 24.8% of the fully-diluted common stock of Protara.

Based on the terms of the Merger, the transaction was treated as a reverse merger of Protara Therapeutics, Inc. by Private ArTara. The Merger was accounted for using acquisition accounting under ASC Topic 805 “Business Combinations”. Under acquisition accounting, the assets and liabilities (including executory contracts, commitments and other obligations) of Protara Therapeutics, Inc. as of the effective time of the Merger were recorded at their respective fair values and added to those of Private ArTara. Any excess of purchase price consideration over the fair values of the identifiable net assets is recorded as goodwill. During the year ended December 31, 2020, the Company recorded an adjustment of $150 to goodwill. This adjustment was comprised of a decrease of $78 in prepaid expenses and other current assets, and an increase of $77 in accrued expenses, resulting in a final purchase price allocation as follows:

Cash	$	3,669
Restricted cash		50
Prepaid expenses and other current assets		1,662
Goodwill		29,517
Accrued expenses		(365	)
Total purchase price consideration	$	34,533

The total fair value of the net assets of Protara Therapeutics Inc. was determined by the Company to be $34,533 based on the consideration transferred. The total consideration was based on the enterprise value of Protara Therapeutics Inc. as of January 9, 2020, based upon the number of common shares deemed outstanding, multiplied by the closing stock price on January 9, 2020.

Of the amount of goodwill acquired in the reverse merger, no portion is deductible for tax purposes.

The primary reasons for the reverse merger were to increase access to sources of capital and a broader range of investors to support the clinical development of Private ArTara’s product candidates, the potential to provide current stockholders with greater liquidity by owning stock in a public company, the potential for a more cost-effective means to access capital and the registration of Protara common stock issued to Private ArTara’s stockholders. In addition, Protara assumed the existing 2014 Equity Incentive Plan, and all outstanding stock options thereunder.

The following presents the unaudited pro forma combined financial information as if the reverse merger had occurred as of January 1, 2020.

	For the Year Ended December 31,
	2020
Net loss	$	(33,754	)
Pro forma loss per common share, basic and diluted	$	(4.62	)
Pro forma weighted average number of common shares outstanding, basic and diluted		7,304,201

The pro forma combined results of operations are not necessarily indicative of the results of operations that would have occurred had the reverse merger been completed as of January 1, 2020, nor are they necessarily indicative of future consolidated results.

Fair Value of Financial Instruments

12 Months Ended

Dec. 31, 2021

Fair Value Disclosures [Abstract]

Fair Value of Financial Instruments

4. Fair Value of Financial Instruments

The table below presents information about the Company’s financial instruments that are measured at fair value on a recurring basis as of December 31, 2021 and indicates the fair value hierarchy of the valuation techniques the Company utilized to determine such fair value, as described under Note 2, Summary of Significant Accounting Policies.

At December 31, 2021, the Company has classified financial instruments measured at fair value on a recurring basis as follows:

	December 31, 2021
	Level 1		Level 2		Level 3		Total
Cash Equivalents
Money market funds	$	26,323	$	-	$	-	$	26,323
Restricted cash, non-current
Money market funds		745		-		-		745
Marketable debt securities
Corporate bonds		-		94,972		-		94,972
Total	$	27,068	$	94,972	$	-	$	122,040

Money market funds are classified as Level 1 within the fair value hierarchy, because they are valued using quoted prices in active markets. Corporate debt securities classified as Level 2 within the fair value hierarchy are valued on the basis of prices from an orderly transaction between market participants provided by reputable dealers or pricing services. Prices of these securities are obtained through independent, third-party pricing services and include market quotations that may include both observable and unobservable inputs. In determining the value of a particular investment, pricing services may use certain information with respect to transactions in such investments, quotations from dealers, pricing matrices and market transactions in comparable investments and various relationships between investments. There were no transfers of financial instruments among Level 1, Level 2, and Level 3 during the period presented.

As of December 31, 2020, the Company did not have any marketable debt securities or money market funds.

Cash equivalents, prepaid expenses and other current assets, accounts payable and accrued expenses at December 31, 2021 and 2020 are carried at amounts that approximate fair value due to their short-term maturities.

- Definition

The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.

+ References + Details

Marketable Debt Securities

12 Months Ended

Dec. 31, 2021

Marketable Debt Securities [Abstract]

Marketable Debt Securities

5. Marketable Debt Securities

Marketable debt securities, all of which were classified as available-for-sale, consist of the following:

	December 31, 2021
	Amortized Cost		Unrealized Gains		Unrealized Losses			Estimated Fair Value
Corporate bonds - presented in marketable debt securities	$	55,548	$	-	$	(43	)	$	55,505
Corporate bonds - presented in marketable debt securities, non-current		39,635		-		(168	)		39,467
Total	$	95,183	$	-	$	(211	)	$	94,972

As of December 31, 2020, the Company did not have any marketable debt securities.

The amount of realized gains and losses reclassified into earnings have not been material to the Company’s consolidated statements of operations. There were no sales of securities in the periods presented.

The contractual maturities of all securities held at December 31, 2020 was 23 months or less. Of the 40 securities in a loss position held by the Company, there were no securities with an other-than-temporary impairment at December 31, 2021. There were no securities in a continuous unrealized loss position for greater than twelve months at December 31, 2021.

Investment Income

Investment income consists of the following:

	December 31,
	2021			2020
Interest income	$	1,974		$	500
Accretion/(amortization) of discount/premium, net		(1,737	)		-
Total interest and investment income	$	237		$	500

Prepaid Expenses and Other Current Assets

12 Months Ended

Dec. 31, 2021

Prepaid Expenses and Other Current Assets [Abstract]

Prepaid Expenses and Other Current Assets

6. Prepaid Expenses and Other Current Assets

Prepaid expenses and other current assets consist of the following:

	December 31,
	2021		2020
Prepaid insurance		279		292
Prepaid research and development		684		209
Prepaid software		79		10
Accrued interest on marketable debt securities		634		-
Prepaid rent		-		113
Other prepaid expenses		173		111
Other current assets		34		52
Total	$	1,883	$	787

Property and Equipment, net

12 Months Ended

Dec. 31, 2021

Property, Plant and Equipment [Abstract]

Property and Equipment, net

7. Property and Equipment, net

Property and equipment, net consists of the following:

	December 31,
	2021			2020
Computer equipment	$	175		$	34
Furniture, fixtures and other		352			21
Laboratory equipment		591			601
Leasehold improvements		224			200
Property and equipment not yet placed into service		613			503
Total property and equipment		1,955			1,359
Less: Accumulated depreciation		(236	)		(119	)
Total property and equipment, net	$	1,719		$	1,240

Depreciation expense was $117 and $103 for the years ended December 31, 2021 and 2020, respectively. During the year ended December 31, 2021, $36 and $81 was included in research and development expense and general and administrative expense, respectively, within the consolidated statements of operations and comprehensive loss. For the year ended December 31, 2020, $99 and $4 was included in research and development expense and general and administrative expense, respectively, within the consolidated statements of operations and comprehensive loss. As of December 31, 2021 and 2020, 100% of the Company’s total property and equipment, net was attributable to the United States.

Accrued Expenses

12 Months Ended

Dec. 31, 2021

Payables and Accruals [Abstract]

Accrued Expenses

8. Accrued Expenses

Accrued expenses consist of the following:

	December 31,
	2021		2020
Payroll	$	1,801	$	1,530
Taxes		41		159
Legal fees		29		156
Research and development costs		437		37
Other expenses		181		31
Total	$	2,489	$	1,913

Short-Term Debt

12 Months Ended

Dec. 31, 2021

Debt Disclosure [Abstract]

Short-Term Debt

9. Short-Term Debt

Financing Agreement

On February 19, 2020, the Company entered into a nine-month financing agreement with AFCO Credit Corporation for its directors and officers (“D&O”) liability insurance in the amount of $2,225. The Company made a down payment of $556, leaving a principal balance of $1,669. The financing bore interest at a rate of 4.25% per annum, and was repaid in monthly installments of $189, which included both principal and interest. As of December 31, 2021 and 2020, the balance under this debt was $0. The Company recorded interest expense of $0 and $34 for the year ended December 31, 2021 and 2020, respectively, under this financing agreement.

Leases

12 Months Ended

Dec. 31, 2021

Leases [Abstract]

Leases

10. Leases

Operating leases

In December 2020, the Company entered into an agreement to lease approximately 10.3 square feet of office space in New York, New York (“Office Lease”), which commenced in April 2021. The office space is owned by an affiliate of Deerfield Management Company, L.P., which together with its affiliates beneficially owned more than 5% of the Company’s voting securities at the time the lease was executed. Annual rent is approximately $1,117. The Office Lease has a term of approximately seven years and contains provisions for a free-rent period, annual rent increases and an allowance for tenant improvements. The Company has an option to extend the term by five years, however, the Company determined at the lease commencement date that it was not reasonably certain to exercise the renewal option and such renewal was excluded from the operating lease right-of-use, or ROU, asset and operating lease liability recorded for this lease.

The Company is responsible for real estate taxes, maintenance and other operating expenses applicable to the leased premises which are recognized as variable lease expense in the period when incurred. In conjunction with the Office Lease, the Company established a letter of credit of approximately $745 secured by cash balances included in restricted cash.

In June 2021, the Company amended the existing agreement with its contract development and manufacturing organization, or CDMO, establishing a term of eight-years from the amendment date. Prior to the amendment, the leased spaces met the short-term lease exception under a quarter-to quarter arrangement and were not included in measurement of lease liabilities.

Leases classified as operating leases are included in operating lease ROU assets, operating lease liabilities and operating lease liabilities, non-current, in the Company’s consolidated balance sheets. The Office Lease and the CDMO leased spaces are included in operating lease ROU assets and operating lease liabilities. Cash paid for operating lease liabilities was $1,009 and $66 during the years ended December 31, 2021 and 2020, respectively, which is included in operating cash flows. The ROU asset obtained in exchange for operating lease liabilities related to the Office Lease was $6,549.

The components of lease expense were as follows:

	For the year ended December 31,
Lease expense	2021		2020
Operating lease expense	$	1,050	$	93
Short-term lease expense		102		215
Total	$	1,152	$	308

Variable lease expense for the years ended December 31, 2021 and 2020 was not material.

The weighted average remaining lease term and the weighted average discount rate for operating leases were:

	For the year ended December 31,
	2021			2020

Weighted-average discount rate		7.0	%		12.0	%
Weighted-average remaining lease term – operating lease (in months)		79			87

The total remaining operating lease payments included in the measurement of lease liabilities on the Company’s consolidated balance sheet as of December 31, 2021, was as follows:

For the year ending December 31:	Operating Lease Payments
2022	$	1,327
2023		1,327
2024		1,327
2025		1,395
2026		1,429
Thereafter		2,234
Total gross operating lease payments		9,039
Less: imputed interest		(1,800	)
Total lease liabilities, reflecting present value of future minimum lease payments	$	7,239

Commitments and Contingencies

12 Months Ended

Dec. 31, 2021

Commitments and Contingencies Disclosure [Abstract]

Commitments and Contingencies

11. Commitments and Contingencies

Employment Agreements

Executive Employment Agreements

The Company’s executive officers have entered into at-will employment agreements.

Collaborations and License Agreements

Choline License Agreement

On September 27, 2017, the Company entered into a license agreement (the “Choline License Agreement”) with Alan L. Buchman (“Dr. Buchman”). Pursuant to the Choline License Agreement, the Company received from Dr. Buchman the license rights in and to the “Licensed Orphan Designations”, the “Licensed IND”, “Existing Study Data” and the “Licensed Know-How” for one or more of the licensed indications.

Pursuant to the agreement there were no research and development expenses recognized during the years ended December 31, 2021 and 2020.

License Agreement

On December 22, 2017, the Company entered into an agreement (the “Feinstein Agreement”) with The Feinstein Institute for Medical Research (the “Feinstein Institute”), a not-for-profit corporation with 50 research labs and 2,500 clinical research studies. Pursuant to the Feinstein Agreement, the Company acquired an exclusive license relating to treatment of fatty liver diseases in humans for which Choline may be an effective therapeutic. In consideration for the rights and license granted, the Feinstein Institute would receive a royalty of one percent (1%) of the first one hundred million dollars ($100,000) of net sales of IV Choline Chloride and a royalty of one and one-half percent (1.5%) of all net sales thereafter. In addition, the Company would pay the Feinstein Institute twelve and one-half percent (12.5%) of net proceeds resulting from agreements entered within 2 years from the effective date, and seven and one-half percent (7.5%) of net proceeds resulting from agreements entered into thereafter. Pursuant to the Feinstein Agreement additional payments would be due to the Feinstein Institute for license maintenance payments and for meeting milestone events. Pursuant to the Feinstein Agreement, upon the achievement of certain future new drug application milestones, the Company would be obligated to remit an aggregate of $275.

During the years ended December 31, 2021 and 2020, the Company recorded research and development expense of $15 and $115, respectively, in connection with the Feinstein Agreement.

Sponsored Research and License Agreement

On November 28, 2018, the Company entered into a sponsored research and license agreement (the “Iowa Agreement”) with the University of Iowa. Pursuant to the Iowa Agreement, the University of Iowa, which is engaged in clinical research to improve the diagnosis and treatment of lymphangioma using a pharmaceutical product (OK-432), would assist the Company in collecting case reports, forms, source data, and safety data available to the University of Iowa in support of the development of the Company’s proprietary Streptococcus Pyogenes investigational product, TARA-002 for the LMs indication. During the term of the services, the Company would generally pay the University of Iowa thirty thousand dollars ($30) per year to fund the project, plus additional amounts upon the realization of certain milestones. More specifically, upon forty-five (45) days of an approval of TARA-002 by the FDA, the Company would pay up to $1,750 to the University of Iowa for meeting these milestones. Furthermore, the Company would pay the University of Iowa royalties of up to 1.75% for net sales ranging from $0 - $25,000, 2.25% for net sales ranging from $25,000 to $50,000, and 2.50% for net sales in excess of $50,000. Pursuant to the Iowa Agreement, the University of Iowa would be entitled to additional payments for the Company achieving annual net sales of product according to the milestones. For annual net sales of product up to $25,000; $62; for annual net sales of product of up to $50,000; $62; and for annual net sales of product of up to $100,000; $125.

During the years ended December 31, 2021 and 2020, the Company recorded research and development expense of $0 and $30 respectively, in connection with the Iowa Agreement.

Chugai Agreement

On June 17, 2019, the Company entered into an agreement (the “Chugai Pharmaceutical Agreement”) with Chugai Pharmaceutical Co., LTD (“Chugai”), a drug manufacturing firm with offices and operations in Japan. Pursuant to the Chugai Pharmaceutical Agreement, Chugai would help the Company in its goals to develop and commercialize a therapeutic product (the “New Product”) which is comparable to the Chugai existing therapeutic product (the “Existing Product”). In addition, the Company would be entitled to the use of Chugai materials and technical support as necessary. On July 14, 2020, the Company and Chugai entered into an amendment (the “Chugai Amendment”) to the Chugai Pharmaceutical Agreement. The Chugai Amendment is effective as of June 30, 2020. The Chugai Amendment extended the date through which Chugai will exclusively provide the Existing Product and materials to the Company from June 30, 2020 to June 30, 2021, extended the date through which Chugai will not provide materials or technical support to any third-party for the purpose of development and commercialization in a given area from the fifth anniversary to the eleventh anniversary of the original effective date and provides that, in addition to the designated fee provided upon the initial indication approval in the Chugai Pharmaceutical Agreement, the Company will pay Chugai a designated fee for each additional indication approval. The Company is obligated to Chugai for certain payments upon the completion of agreed upon milestones.

Pursuant to the agreement there were no research and development expenses recognized during the years ended December 31, 2021 and 2020.

Litigation

From time to time, Protara may be subject to various legal proceedings and claims that arise in the ordinary course of its business activities. Management is of the opinion that the ultimate outcome of these matters would not have a material adverse impact on the financial position of the Company or the results of its operations.

In the normal course of business, the Company enters into contracts in which it makes representations and warranties regarding the performance of its services and that its services will not infringe on third-party intellectual rights. There have been no significant events related to such representations and warranties in which the Company believes the outcome could result in losses or penalties in the future.

Stockholders’ Equity

12 Months Ended

Dec. 31, 2021

Stockholders' Equity Note [Abstract]

Stockholders’ Equity

12. Stockholders’ Equity

Common Stock

As of December 31, 2021, the Company had 100,000,000 shares of common stock authorized for issuance, $0.001 par value per share, of which 11,235,731 and 11,211,840 shares were issued and outstanding as of December 31, 2021 and 2020, respectively.

The holders of the Company’s common stock are entitled to one vote per share.

Preferred Stock

In connection with the Preferred Offering (defined below) on September 22, 2020, the Company filed a Certificate of Amendment to the Certificate of Designation of Preferences, Rights and Limitations of Series 1 Convertible Preferred Stock of the Company (the “Amendment”) with the State of Delaware to increase the authorized number of shares of the Company’s Series 1 Convertible Preferred Stock that may be issued from 3,880 to 8,028. The Amendment was approved by a committee of the Company’s Board of Directors and the requisite holders of outstanding shares of Series 1 Convertible Preferred Stock. No approval of the holders of the Company’s common stock was required to effectuate the Amendment.

As of December 31, 2021 and 2020, the Company had 10,000,000 shares of preferred stock authorized for issuance, $0.001 par value per share of which 8,028 shares of Series 1 Convertible Preferred Stock are authorized for issuance and 8,027 shares were issued and outstanding, respectively.

Description of Series 1 Convertible Preferred Stock

Each share of Series 1 Convertible Preferred Stock is convertible into 1,000 shares of the Company’s common stock, at a conversion price initially equal to approximately $7.01 per common share, subject to adjustment for any stock splits, stock dividends and similar events, at any time at the option of the holder, provided that any conversion of Series 1 Convertible Preferred Stock by a holder into shares of the Company’s common stock would be prohibited if, as a result of such conversion, the holder, together with its affiliates and any other person or entity whose beneficial ownership of the Company’s common stock would be aggregated with such holder’s for purposes of Section 13(d) of the Securities Exchange Act of 1934, as amended, would beneficially own more than 9.99% of the total number of shares of the Company’s common stock issued and outstanding after giving effect to such conversion. Upon written notice to the Company, the holder may from time to time increase or decrease such limitation to any other percentage not in excess of 19.99% specified in such notice. In addition, upon the occurrence of certain transactions that involve the merger or consolidation of the Company, an exchange or tender offer, a sale of all or substantially all of the assets of the Company or a reclassification of its Common Stock, each share of Series 1 Convertible Preferred Stock will be convertible into the kind and amount of securities, cash and/or other property that the holder of a number of shares of Common Stock issuable upon conversion of one share of Series 1 Convertible Preferred Stock would receive in connection with such transaction.

The terms of the Series 1 Convertible Preferred Stock provide that, in the event of a fundamental transaction (as such term is described in the certificate of designation of preferences, rights and limitations of series 1 convertible non-voting preferred stock), each share of Series 1 Convertible Preferred Stock outstanding shall thereafter be convertible into the kind and amount of securities, cash and/or other property which a holder of the number of shares of Common Stock of the Company issuable upon conversion of one share of Series 1 Convertible Preferred Stock immediately prior to such fundamental transaction would have been entitled to receive pursuant to such fundamental transaction, provided that, if the value of the aggregate of such securities, cash and/or other property the which the holder of one share of Series 1 Convertible Preferred Stock would be entitled to upon conversion thereof would be less than the stated value, then each outstanding share of Series 1 Convertible Preferred Stock shall instead be convertible into such kind of securities, cash and/or other property with an aggregate value equal to the stated value.

Each share of Series 1 Convertible Preferred Stock is entitled to a preference of $10.00 per share upon liquidation of the Company, and thereafter will share ratably in any distributions or payments on an as-converted basis with the holders of Common Stock. The Company’s Series 1 Convertible Preferred Stock are non-voting.

Underwritten Public Offering

On September 24, 2020, pursuant to an underwriting agreement dated September 22, 2020, the Company issued and sold in an underwritten public offering (the “Common Offering”) an aggregate of 4,600,000 shares of its common stock at an offering price of $16.87 per share, for gross and net proceeds of approximately $77.6 million and $73.6 million, respectively. The underwriters were granted an option to purchase up to 690,000 additional shares of the Company’s common stock at the public offering price, less the underwriting discount. On October 6, 2020, the underwriters exercised their overallotment option in full, purchasing an additional 690,000 shares, resulting in the receipt of gross and net proceeds of $11.6 million and $11.1 million, respectively.

On September 24, 2020, pursuant to an underwriting agreement (dated September 22, 2020), the Company issued and sold in an underwritten public offering (the “Preferred Offering”) an aggregate of 4,148 shares of its Series 1 Convertible Preferred Stock at an offering price of $16,873.54 per share, for gross and net proceeds of approximately $70.0 million and $66.3 million, respectively.

- Definition

The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 13
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 13
-URI http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 14
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=123467817&loc=SL123496171-112644

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 14
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=123467817&loc=SL123496171-112644

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.3-04)
-URI http://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 18
-Subparagraph (d)
-URI http://asc.fasb.org/extlink&oid=123467817&loc=SL123496189-112644

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 13
-Subparagraph (g)
-URI http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644

Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-URI http://asc.fasb.org/topic&trid=2208762

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 18
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=123467817&loc=SL123496189-112644

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 13
-Subparagraph (h)
-URI http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 14
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=123467817&loc=SL123496171-112644

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 18
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=123467817&loc=SL123496189-112644

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 16
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=123467817&loc=SL123496180-112644

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 13
-Subparagraph (i)
-URI http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644

Reference 15: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(e)(1))
-URI http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690

+ Details

Stock-Based Compensation

12 Months Ended

Dec. 31, 2021

Share-based Payment Arrangement [Abstract]

Stock-Based Compensation

13. Stock-Based Compensation

2020 Inducement Plan

On March 26, 2020, the Compensation Committee of the Board of Directors (the “Compensation Committee”) approved the ArTara Therapeutics, Inc. Inducement Plan (the “2020 Inducement Plan”) in order to award nonstatutory stock options, restricted stock awards, restricted stock unit awards and other stock-based awards to persons not previously an employee or director of the Company, or following a bona fide period of non-employment, as an inducement material to such persons entering into employment with the Company.

The 2020 Inducement Plan provides for a total of 600,000 shares for the issuance of the Company’s common stock. The Compensation Committee also adopted a form of stock option grant notice and stock option agreement and forms of restricted stock unit grant notice and restricted stock unit agreement for use with the Inducement Plan.

As of December 31, 2021, 420,500 shares remain available to be issued under the 2020 Inducement Plan.

2017 Equity Incentive Plan

On August 10, 2017, Private ArTara, its Board of Directors and its shareholders approved the ArTara Therapeutics, Inc. 2017 Equity Incentive Plan to enable Private ArTara and its affiliates to recruit and retain highly qualified personnel and to incentivize personnel for productivity and growth.

The 2017 Equity Incentive Plan provided for the grant of a total of 2,000,000 shares for the issuance of stock options, stock appreciation rights, restricted stock and restricted stock units to among others, members of the Board of Directors, employees, consultants and service providers to the Company and its affiliates. As of January 9, 2020, in connection with the Merger, no additional awards will be made under the 2017 Equity Incentive Plan.

2014 Equity Incentive Plan

On October 3, 2014, the stockholders approved the 2014 Equity Incentive Plan. On June 20, 2017, the Company’s Board of Directors amended the 2014 Equity Incentive Plan (the “Amended 2014 Plan”). On July 31, 2017, the stockholders approved this amendment. On January 1, 2020, Protara Therapeutics, Inc. amended its Amended and Restated 2014 Equity Incentive Plan to increase the number of shares of stock available for issuance under the 2014 Equity Incentive Plan to 1,048,300 shares and made conforming changes and updates pursuant to Section 162(m) of the Code.

The Amended 2014 Plan provides for the grant of incentive and non-statutory stock options, stock appreciation rights, restricted stock and stock unit awards, performance units, stock grants and qualified performance-based awards. The Amended 2014 Plan provides that the number of shares reserved and available for issuance will automatically increase each January 1, by four percent of the Company’s common stock on the immediately preceding December 31, adjusted for the number of shares of the Company’s common stock issuable upon conversion of any security that the Company may issue that is convertible into or exchangeable for the Company’s common stock, or such lesser number of shares as determined by the Company’s Board of Directors. On January 1, 2021, pursuant to the Amended 2014 Plan’s annual evergreen feature, the number of shares authorized under the Amended 2014 Plan was increased by 812,889 shares to 1,861,189 shares. As of December 31, 2021, 398,604 shares remain available to be issued under the Amended 2014 Plan.

On January 1, 2022, pursuant to the Amended 2014 Plan’s annual evergreen feature, the number of shares authorized under the Amended 2014 Plan was increased by 840,181 shares to 1,238,785 shares available to be issued.

Terms of the stock awards, including vesting requirements, are determined by the Board of Directors, subject to the provisions of the plans. Certain awards provide for accelerated vesting if there is a change in control as defined in the plans.

2014 Employee Stock Purchase Plan

On October 3, 2014, the stockholders approved the 2014 Employee Stock Purchase Plan (the “2014 ESPP”). The 2014 ESPP initially authorized the issuance of up to 3,513 shares of the Company’s common stock. The number of shares increases each January 1, commencing on January 1, 2015 and ending on (and including) January 1, 2024, by an amount equal to the lesser of one percent of the outstanding shares as of the end of the immediately preceding fiscal year, 7,025 shares or any lower amount determined by the Company’s Board of Directors prior to each such January 1st. On January 1, 2021, pursuant to the increase per the 2014 ESPP, the number of shares authorized under the 2014 ESPP was increased by 7,025 shares to 25,037 shares. As of December 31, 2021, the authorized number of shares under the 2014 ESPP is 25,037 and the number of shares available for issuance is 20,365. During the years ended December 31, 2021 and 2020, no shares were issued under the 2014 ESPP.

On January 1, 2022, pursuant to the increase per the 2014 ESPP, the number of shares authorized under the 2014 ESPP was increased by 7,025 shares to 32,062 shares.

Restricted Stock Units

The following table summarizes restricted stock unit activity:

	Restricted Stock Units			Weighted Average Grant Date Fair Value
Non-vested 12/31/2020		274,616		$	29.95
Granted		10,500			11.16
Forfeited		-			-
Vested		(188,915	)		29.46
Non-vested 12/31/2021		96,201		$	28.87

The fair value of RSUs is amortized on a straight-line basis over the requisite service period of the respective awards. As of December 31, 2021, the unamortized value of RSUs was $1,835. As of December 31, 2021, the weighted average remaining amortization period was 2.39 years. As of December 31, 2021 and 2020, 286,918 and 132,709 RSUs, respectively, have vested that have not yet been settled into shares of the Company’s common stock.

During the year ended December 31, 2021, the Company issued 23,891 shares of the Company’s common stock from the net settlement of 34,706 RSUs. The Company paid $228 in connection with the net share settlement of these RSUs.

Stock Options

The Company determined the fair value of stock options granted based upon the assumptions as provided below.

	For the Years Ended December 31,
	2021			2020
Exercise price		$ 6.56 - $ 19.82			$ 17.84 - $ 51.12
Dividend yield		0.00	%		0.00	%
Expected volatility		89.00% - 98.00	%		95.00% - 101.00	%
Risk-free interest rate		0.45% - 1.33	%		0.28% - 1.69	%
Expected life (in years)		5.27 - 6.08			5.27 - 6.08

The following table summarizes stock option activities for the year ended December 31, 2021:

	Number of Options			Weighted Average Exercise Price		Weighted Average Remaining Contractual Term (years)		Aggregate Intrinsic Value (1)
Outstanding 12/31/2020		674,039		$	25.23		9.06	$	2,311
Granted		861,850			16.32		-		-
Exercised		-			-		-		-
Forfeited		(168,196	)		17.62		-		-
Expired		(11,054	)		26.15		-		-
Outstanding at December 31, 2021		1,356,639		$	20.51		8.59	$	1

Vested or expected to vest at December 31, 2021		1,356,639		$	20.51		8.59	$	-
Exercisable as of 12/31/2021		407,981		$	21.97		7.83	$	-

(1)

Aggregate intrinsic value represents the difference between the exercise price of the option and the closing market price of our common stock on December 31, 2021. The intrinsic value of options exercised during the year ended December 31, 2021 was $0 as no options were exercised. The intrinsic value of options exercised during the year ended December 31, 2020 was $696.

The weighted average grant date fair value per share of the options granted during the years ended December 31, 2021 and 2020 was $12.60 and $22.61, respectively of December 31, 2021, there was approximately $12,664 of unrecognized share-based compensation for unvested stock option grants which is expected to be recognized over a weighted average period of 2.71 years. The total unrecognized share-based compensation cost will be adjusted for actual forfeitures as they occur.

Summary of Stock-Based Compensation Expense

The following tables summarize total stock-based compensation costs recognized:

	For the Years Ended December 31,
	2021		2020
RSUs	$	4,520	$	6,357
Stock options		5,842		3,389
Total	$	10,362	$	9,746

Stock-based compensation expense was reflected within the statements of operations as:

	For the Years Ended December 31,
	2021		2020
Research and development	$	1,409	$	741
General and administrative		8,953		9,005
Total	$	10,362	$	9,746

Income Taxes

12 Months Ended

Dec. 31, 2021

Income Tax Disclosure [Abstract]

Income Taxes

14. Income Taxes

Federal and State income tax expense is as follows:

	For the Years Ended December 31,
	2021			2020
Current
Federal	$	-		$	-
State		-			-
Total current		-			-
Deferred
Federal		(8,918	)		(6,211	)
State		4,294			(2,439	)
Total deferred		(4,624	)		(8,650	)
Change in valuation allowance		4,624			8,650
Total income tax expense (benefit)	$	-		$	-

Deferred income taxes, if applicable, are provided for the differences between the basis of assets and liabilities for financial reporting and income tax purposes.

The tax effects of temporary differences that give rise to significant portions of the deferred tax assets are as follows:

	As of December 31,
	2021			2020
Deferred tax assets:
Net operating loss carry forwards	$	23,350		$	19,371
Stock option expense		920			443
Research and development credits		1,551			70
Operating lease liability		1,564			330
RSU expense		1,960			1,796
Other		7			10
Total deferred tax assets		29,352			22,020
Valuation allowance		(27,803	)		(21,698	)
Deferred tax assets, net of valuation allowance		1,549			322
Deferred tax liabilities:
Operating right-of-use asset		(1,549	)		(322	)
Total deferred tax liabilities		(1,549	)		(322	)
Deferred tax assets, net of valuation allowance and deferred tax liabilities	$	-		$	-

A reconciliation of the provision for income taxes with the amounts computed by applying the statutory Federal income tax to income before provision for income taxes is as follows:

	For the Years Ended December 31,
	2021			2020
U.S. federal statutory rate		(21.0	)%		(21.0	)%
State taxes, net of federal benefit		(0.6	)%		(9.4	)%
Research and development credits		(3.3	)%		-	%
Option expense		1.1	%		1.2	%
Other		1.2	%		1.9	%
True-up to prior years return		8.2	%		1.8	%
State rate change		1.5	%		-	%
Change in valuation allowance		12.9	%		25.5	%
Effective tax rate		-	%		-	%

For the year ended December 31, 2020, the Company’s effective tax rate was 0%, which consisted principally of a federal rate of 21% and the Company’s estimate of state taxes, net of federal benefit, of 9.4%, offset by a valuation allowance 25.5%. For the year ended December 31, 2021, the Company’s effective tax rate was 0%, which consisted principally of a federal rate of 21%, and the Company’s estimate of state taxes, net of federal benefit, of 0.6%, offset by a valuation allowance 12.9% and true-up to the prior years tax return of 8.2%.

As of December 31, 2021 for U.S. federal and state income tax reporting purposes, the Company has approximately $100.2 million and $29.6 million, respectively, of unused net operating losses (“NOLs”) available for carry forward to future years. As a result of the Tax Cuts and Jobs Act of 2017 (“TCJA”), for U.S. income tax purposes, NOLs generated in tax years beginning before January 1, 2018 can still be carried forward for up to 20 years, but net operating losses generated for tax years beginning after December 31, 2017 carryforward indefinitely and can be used to offset taxable income. Of the total Federal NOL, $0.6 million can be carried forward until 2037; and $99.6 million can be carried forward indefinitely. The New York state and city NOLs may be carried forward through the year 2041 and may be applied against future taxable income. Further, the benefit from utilization of NOL carry forwards could be subject to limitations due to material ownership changes that could occur as the Company continues to issue additional shares of common stock pursuant to its capital raising plans. Based on such limitations, the Company has significant NOLs for which realization of tax benefits is uncertain. The Company has not performed a study to determine whether or not there is such a limitation.

The Company remains subject to examination by tax authorities for all tax years.

Based on a history of cumulative losses at the Company and the results of operations for the years ended December 31, 2021 and 2020, the Company determined that it is more likely than not that it will not realize benefits from the net deferred tax assets. The Company will not record income tax benefits in the financial statements until it is determined that it is more likely than not that the Company will generate sufficient taxable income to realize the deferred income tax assets. As a result of the analysis, the Company determined that a full valuation allowance against the deferred tax assets, net, was required. As of December 31, 2021 and 2020, the Company has recorded a valuation allowance of $27.8 million and $21.7 million, respectively.

As of December 31, 2021 and 2020, management does not believe that the Company has any material uncertain tax positions that would require it to measure and reflect the potential lack of sustainability of a position on audit in its consolidated financial statements. The Company will continue to evaluate its uncertain tax positions in future periods to determine if measurement and recognition in its financial statements is necessary. The Company does not believe there will be any material changes in its unrecognized tax positions over the next year.

- Definition

The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 21
-URI http://asc.fasb.org/extlink&oid=121826272&loc=d3e32857-109319

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SAB Topic 11.C)
-URI http://asc.fasb.org/extlink&oid=122134291&loc=d3e330215-122817

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 17
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=121826272&loc=d3e32809-109319

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SAB TOPIC 6.I.5.Q1)
-URI http://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 14
-URI http://asc.fasb.org/extlink&oid=121826272&loc=d3e32705-109319

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 270
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6424409&loc=d3e44925-109338

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-URI http://asc.fasb.org/topic&trid=2144680

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 30
-Section 50
-Paragraph 2
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=6424122&loc=d3e41874-109331

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(h)(2))
-URI http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690

+ Details

Employee Benefit Plan

12 Months Ended

Dec. 31, 2021

Retirement Benefits [Abstract]

Employee Benefit Plan

15. Employee Benefit Plan

The Company maintains a defined contribution benefit plan under section 401(k) of the Internal Revenue Code covering substantially all qualified employees of the Company (the “401(k) Plan”). Under the 401(k) Plan, the Company matches 100% up to a 4% contribution. The 401(k) Plan was implemented in June of 2020. For the years ended December 31, 2021 and 2020, the Company recorded expense of $215 and $69, respectively, representing employer contributions under the 401(k) Plan.

Net Loss Per Common Share

12 Months Ended

Dec. 31, 2021

Earnings Per Share [Abstract]

Net Loss Per Common Share

16. Net Loss per Common Share

The following table sets forth the computation of the net loss per share attributable to common stockholders, basic and diluted:

	December 31,
	2021			2020
Numerator:
Net loss attributable to common stockholders	$	47,252		$	33,978
Denominator:
Weighted-average common shares outstanding – basic and diluted		11,232,576			7,233,913
Net loss per share attributable to common stockholders, basic and diluted	$	(4.21	)	$	(4.70	)

Since the Company was in a net loss position for all periods presented, net loss per share attributable to common stockholders was the same on a basic and diluted basis, as the inclusion of all potential common equivalent shares outstanding would have been anti-dilutive. The Company excluded the following potential common shares, presented based on amounts outstanding at each period end, from the computation of diluted net loss per share attributable to common stockholders for the periods indicated because including them would have had an anti-dilutive effect:

	December 31,
	2021		2020
Stock options issued and outstanding		1,356,639		674,039
Restricted stock units issued and outstanding		383,119		407,325
Conversion of Series 1 Convertible Preferred Stock		8,029,039		8,029,039
Total potentially dilutive shares		9,768,797		9,110,403

Accounting Policies, by Policy (Policies)

12 Months Ended

Dec. 31, 2021

Accounting Policies [Abstract]

Basis of Presentation

Basis of Presentation

The accompanying consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (“U.S. GAAP” or “GAAP”).

Principles of Consolidation

Principles of Consolidation

Use of Estimates

Reclassification

Business Combinations

Cash, Cash Equivalents and Restricted Cash

The following table provides a reconciliation of cash, cash equivalents, and restricted cash in the consolidated balance sheets to the total amount shown in the consolidated statements of cash flows:

	December 31,
	2021		2020
Cash and cash equivalents	$	35,724	$	168,598
Restricted cash		-		50
Restricted cash, non-current		745		745
Total cash, cash equivalents and restricted cash shown in the consolidated statements of cash flows	$	36,469	$	169,393

Fair Value Measurements

	Ø	Level 1 Quoted prices in active markets for identical assets or liabilities.

	Ø	Level 2 Quoted prices for similar assets or liabilities in active markets, quoted prices for identical or similar assets or liabilities in markets that are not active, or other inputs that are observable, either directly or indirectly.

Level 3 Significant unobservable inputs that cannot be corroborated by market data.

The carrying amounts of cash and cash equivalents, prepaid expenses and accounts payable approximate their fair values due to the short-term nature of these instruments.

Marketable Debt Securities

Concentrations of Credit Risk

Property and Equipment, net

The estimated useful lives for significant property and equipment categories are as follows:

Asset Classification		Estimated Useful Life
Computer equipment		5
Furniture, fixtures and other		5
Laboratory equipment		7
Leasehold improvements		Shorter of the useful life of asset or the lease term

Impairment of Long-Lived Assets

Leases

Leases

Segment Information

Goodwill

Research and Development

Patent Costs

Investment Income

Stock-Based Compensation

The fair values of RSUs are based on the fair market value of the Company’s common stock on the date of the grant.

Income Taxes

Net Loss Per Share Attributable to Common Stockholders

Recently Adopted Accounting Pronouncements

Recent Accounting Pronouncements Not Yet Adopted

Subsequent Events

Summary of Significant Accounting Policies (Tables)

12 Months Ended

Dec. 31, 2021

Accounting Policies [Abstract]

Schedule of cash, cash equivalents, and restricted cash

	December 31,
	2021		2020
Cash and cash equivalents	$	35,724	$	168,598
Restricted cash		-		50
Restricted cash, non-current		745		745
Total cash, cash equivalents and restricted cash shown in the consolidated statements of cash flows	$	36,469	$	169,393

Schedule of estimated useful lives for significant property and equipment

Asset Classification		Estimated Useful Life
Computer equipment		5
Furniture, fixtures and other		5
Laboratory equipment		7
Leasehold improvements		Shorter of the useful life of asset or the lease term

Reverse Merger with Protara and Recapitalization (Tables)

12 Months Ended

Dec. 31, 2021

Disclosure Text Block Supplement [Abstract]

Schedule of preliminary allocation of the purchase price consideration

Cash	$	3,669
Restricted cash		50
Prepaid expenses and other current assets		1,662
Goodwill		29,517
Accrued expenses		(365	)
Total purchase price consideration	$	34,533

Schedule of unaudited pro forma combined financial information

	For the Year Ended December 31,
	2020
Net loss	$	(33,754	)
Pro forma loss per common share, basic and diluted	$	(4.62	)
Pro forma weighted average number of common shares outstanding, basic and diluted		7,304,201

Fair Value of Financial Instruments (Tables)

12 Months Ended

Dec. 31, 2021

Fair Value Disclosures [Abstract]

Schedule of financial instruments measured at fair value on a recurring basis

	December 31, 2021
	Level 1		Level 2		Level 3		Total
Cash Equivalents
Money market funds	$	26,323	$	-	$	-	$	26,323
Restricted cash, non-current
Money market funds		745		-		-		745
Marketable debt securities
Corporate bonds		-		94,972		-		94,972
Total	$	27,068	$	94,972	$	-	$	122,040

Marketable Debt Securities (Tables)

12 Months Ended

Dec. 31, 2021

Marketable Debt Securities [Abstract]

Schedule of marketable debt securities

	December 31, 2021
	Amortized Cost		Unrealized Gains		Unrealized Losses			Estimated Fair Value
Corporate bonds - presented in marketable debt securities	$	55,548	$	-	$	(43	)	$	55,505
Corporate bonds - presented in marketable debt securities, non-current		39,635		-		(168	)		39,467
Total	$	95,183	$	-	$	(211	)	$	94,972

Schedule of investment income

	December 31,
	2021			2020
Interest income	$	1,974		$	500
Accretion/(amortization) of discount/premium, net		(1,737	)		-
Total interest and investment income	$	237		$	500

Prepaid Expenses and Other Current Assets (Tables)

12 Months Ended

Dec. 31, 2021

Prepaid Expenses and Other Current Assets [Abstract]

Schedule of prepaid expenses and other current assets

	December 31,
	2021		2020
Prepaid insurance		279		292
Prepaid research and development		684		209
Prepaid software		79		10
Accrued interest on marketable debt securities		634		-
Prepaid rent		-		113
Other prepaid expenses		173		111
Other current assets		34		52
Total	$	1,883	$	787

Property and Equipment, net (Tables)

12 Months Ended

Dec. 31, 2021

Property, Plant and Equipment [Abstract]

Schedule of property and equipment consists

	December 31,
	2021			2020
Computer equipment	$	175		$	34
Furniture, fixtures and other		352			21
Laboratory equipment		591			601
Leasehold improvements		224			200
Property and equipment not yet placed into service		613			503
Total property and equipment		1,955			1,359
Less: Accumulated depreciation		(236	)		(119	)
Total property and equipment, net	$	1,719		$	1,240

Accrued Expenses (Tables)

12 Months Ended

Dec. 31, 2021

Payables and Accruals [Abstract]

Schedule of accrued expenses

	December 31,
	2021		2020
Payroll	$	1,801	$	1,530
Taxes		41		159
Legal fees		29		156
Research and development costs		437		37
Other expenses		181		31
Total	$	2,489	$	1,913

Leases (Tables)

12 Months Ended

Dec. 31, 2021

Leases [Abstract]

Schedule of lease cost

	For the year ended December 31,
Lease expense	2021		2020
Operating lease expense	$	1,050	$	93
Short-term lease expense		102		215
Total	$	1,152	$	308

Schedule of other information related to leases

	For the year ended December 31,
	2021			2020

Weighted-average discount rate		7.0	%		12.0	%
Weighted-average remaining lease term – operating lease (in months)		79			87

Schedule of annual minimum lease payments of operating lease liabilities

For the year ending December 31:	Operating Lease Payments
2022	$	1,327
2023		1,327
2024		1,327
2025		1,395
2026		1,429
Thereafter		2,234
Total gross operating lease payments		9,039
Less: imputed interest		(1,800	)
Total lease liabilities, reflecting present value of future minimum lease payments	$	7,239

Stock-Based Compensation (Tables)

12 Months Ended

Dec. 31, 2021

Share-based Payment Arrangement [Abstract]

Schedule of restricted stock unit activities

	Restricted Stock Units			Weighted Average Grant Date Fair Value
Non-vested 12/31/2020		274,616		$	29.95
Granted		10,500			11.16
Forfeited		-			-
Vested		(188,915	)		29.46
Non-vested 12/31/2021		96,201		$	28.87

Schedule of the fair value of stock options granted

	For the Years Ended December 31,
	2021			2020
Exercise price		$ 6.56 - $ 19.82			$ 17.84 - $ 51.12
Dividend yield		0.00	%		0.00	%
Expected volatility		89.00% - 98.00	%		95.00% - 101.00	%
Risk-free interest rate		0.45% - 1.33	%		0.28% - 1.69	%
Expected life (in years)		5.27 - 6.08			5.27 - 6.08

Schedule of stock option activities

	Number of Options			Weighted Average Exercise Price		Weighted Average Remaining Contractual Term (years)		Aggregate Intrinsic Value (1)
Outstanding 12/31/2020		674,039		$	25.23		9.06	$	2,311
Granted		861,850			16.32		-		-
Exercised		-			-		-		-
Forfeited		(168,196	)		17.62		-		-
Expired		(11,054	)		26.15		-		-
Outstanding at December 31, 2021		1,356,639		$	20.51		8.59	$	1

Vested or expected to vest at December 31, 2021		1,356,639		$	20.51		8.59	$	-
Exercisable as of 12/31/2021		407,981		$	21.97		7.83	$	-

(1)

Schedule of total stock-based compensation costs

	For the Years Ended December 31,
	2021		2020
RSUs	$	4,520	$	6,357
Stock options		5,842		3,389
Total	$	10,362	$	9,746

Schedule of stock-based compensation expense

	For the Years Ended December 31,
	2021		2020
Research and development	$	1,409	$	741
General and administrative		8,953		9,005
Total	$	10,362	$	9,746

Income Taxes (Tables)

12 Months Ended

Dec. 31, 2021

Income Tax Disclosure [Abstract]

Schedule of federal and state income tax expense

	For the Years Ended December 31,
	2021			2020
Current
Federal	$	-		$	-
State		-			-
Total current		-			-
Deferred
Federal		(8,918	)		(6,211	)
State		4,294			(2,439	)
Total deferred		(4,624	)		(8,650	)
Change in valuation allowance		4,624			8,650
Total income tax expense (benefit)	$	-		$	-

Schedule of deferred tax assets and liabilities

	As of December 31,
	2021			2020
Deferred tax assets:
Net operating loss carry forwards	$	23,350		$	19,371
Stock option expense		920			443
Research and development credits		1,551			70
Operating lease liability		1,564			330
RSU expense		1,960			1,796
Other		7			10
Total deferred tax assets		29,352			22,020
Valuation allowance		(27,803	)		(21,698	)
Deferred tax assets, net of valuation allowance		1,549			322
Deferred tax liabilities:
Operating right-of-use asset		(1,549	)		(322	)
Total deferred tax liabilities		(1,549	)		(322	)
Deferred tax assets, net of valuation allowance and deferred tax liabilities	$	-		$	-

Schedule of federal income tax to income before provision for income taxes

	For the Years Ended December 31,
	2021			2020
U.S. federal statutory rate		(21.0	)%		(21.0	)%
State taxes, net of federal benefit		(0.6	)%		(9.4	)%
Research and development credits		(3.3	)%		-	%
Option expense		1.1	%		1.2	%
Other		1.2	%		1.9	%
True-up to prior years return		8.2	%		1.8	%
State rate change		1.5	%		-	%
Change in valuation allowance		12.9	%		25.5	%
Effective tax rate		-	%		-	%

Net Loss Per Common Share (Tables)

12 Months Ended

Dec. 31, 2021

Earnings Per Share [Abstract]

Schedule of net loss per share attributable to common stockholders, basic and diluted

	December 31,
	2021			2020
Numerator:
Net loss attributable to common stockholders	$	47,252		$	33,978
Denominator:
Weighted-average common shares outstanding – basic and diluted		11,232,576			7,233,913
Net loss per share attributable to common stockholders, basic and diluted	$	(4.21	)	$	(4.70	)

Schedule of weighted average dilutive common shares

	December 31,
	2021		2020
Stock options issued and outstanding		1,356,639		674,039
Restricted stock units issued and outstanding		383,119		407,325
Conversion of Series 1 Convertible Preferred Stock		8,029,039		8,029,039
Total potentially dilutive shares		9,768,797		9,110,403

Summary of Significant Accounting Policies (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Accounting Policies [Abstract]
Carrying value of goodwill	$ 29.5	$ 29.5
Percentage of largest amount of benefit	50.00%

Summary of Significant Accounting Policies (Details) - Schedule of cash, cash equivalents, and restricted cash - USD ($) $ in Thousands	Dec. 31, 2021	Dec. 31, 2020
Schedule of cash, cash equivalents, and restricted cash [Abstract]
Cash and cash equivalents	$ 35,724	$ 168,598
Restricted cash		50
Restricted cash, non-current	745	745
Total cash, cash equivalents and restricted cash shown in the consolidated statements of cash flows	$ 36,469	$ 169,393

Summary of Significant Accounting Policies (Details) - Schedule of estimated useful lives for significant property and equipment	12 Months Ended
	Dec. 31, 2021
Computer Equipment [Member]
Summary of Significant Accounting Policies (Details) - Schedule of estimated useful lives for significant property and equipment [Line Items]
Property and equipment	5 years
Furniture, Fixtures and Other [Member]
Summary of Significant Accounting Policies (Details) - Schedule of estimated useful lives for significant property and equipment [Line Items]
Property and equipment	5 years
Laboratory Equipment [Member]
Summary of Significant Accounting Policies (Details) - Schedule of estimated useful lives for significant property and equipment [Line Items]
Property and equipment	7 years
Leasehold Improvements [Member]
Summary of Significant Accounting Policies (Details) - Schedule of estimated useful lives for significant property and equipment [Line Items]
Leasehold improvements	Shorter of the useful life of asset or the lease term

Reverse Merger with Protara and Recapitalization (Details) $ in Thousands	12 Months Ended
	Dec. 31, 2021 USD ($) shares	Dec. 31, 2020 USD ($)	Jan. 01, 2020 shares
Reverse Merger with Protara and Recapitalization (Details) [Line Items]
Reverse stock split	On January 9, 2020, in connection with, and prior to the completion of the Merger, Protara Therapeutics, Inc. effected the Protara Reverse Stock Split, which resulted in 557,631 pre-merger shares of Protara Therapeutics, Inc. outstanding.
Common shares exchange ratio	0.190756
Common stock outstanding	2,627,533
Shares available for issuance	20,365
Pre merger shares	557,631
Reverse business combination	1,033,907
Description of ownership rights	Immediately after the consummation of the Merger and prior to the consummation of the Proteon Private Placement, the former stockholders and option holders of Private ArTara owned, or held rights to acquire, approximately 75.2% of the fully diluted common stock of Protara, with Protara Therapeutics, Inc.’s stockholders and option holders immediately prior to the Merger owning approximately 24.8% of the fully-diluted common stock of Protara.
Goodwill (in Dollars) \| $		$ 150
Prepaid expenses (in Dollars) \| $	$ 78
Accrued expenses (in Dollars) \| $	77
Fair value of net assets (in Dollars) \| $	$ 34,533
2017 Equity Incentive Plan [Member]
Reverse Merger with Protara and Recapitalization (Details) [Line Items]
Shares available for issuance	219,699
2014 Equity Incentive Plan [Member]
Reverse Merger with Protara and Recapitalization (Details) [Line Items]
Shares available for issuance	398,604		1,048,300
Common Stock [Member]
Reverse Merger with Protara and Recapitalization (Details) [Line Items]
Common shares exchange ratio	0.190756
Private Placement [Member]
Reverse Merger with Protara and Recapitalization (Details) [Line Items]
Subscription agreement, description	(i) 3,879.356 of shares of Protara Therapeutics, Inc.’s Series 1 Convertible Non-Voting Preferred Stock at a purchase price of approximately $7,011.47 per share for gross proceeds of $27,200 and proceeds, net of issuance costs, of $25,319, (ii) 1,896,888 shares of Protara Therapeutics, Inc.’s common stock at a purchase price of approximately $7.01 per share for gross proceeds of $13,300 and proceeds, net of issuance costs, of $12,413 and (B) Private ArTara issued in a private placement immediately prior to the Merger (the “ArTara Private Placement”) 284,875 shares of Private ArTara common stock (post-Exchange Ratio basis) at a purchase price of approximately $7.01 per share (post-Exchange Ratio basis) (together with the Proteon Private Placement, the “Private Placements”) for gross proceeds of $2,000 and proceeds, net of issuance costs, of $1,867. The shares issued in the Proteon Private Placement were registered for resale on a registration statement on Form S-3 filed and declared effective by the SEC on January 30, 2020.
Converted shares issued	18,954
Series A Convertible Preferred Stock [Member]
Reverse Merger with Protara and Recapitalization (Details) [Line Items]
Convertible preferred stock	476,276

Reverse Merger with Protara and Recapitalization (Details) - Schedule of preliminary allocation of the purchase price consideration $ in Thousands	12 Months Ended
	Dec. 31, 2020 USD ($)
Schedule of preliminary allocation of the purchase price consideration [Abstract]
Cash	$ 3,669
Restricted cash	50
Prepaid expenses and other current assets	1,662
Goodwill	29,517
Accrued expenses	(365)
Total purchase price consideration	$ 34,533

Reverse Merger with Protara and Recapitalization (Details) - Schedule of unaudited pro forma combined financial information $ / shares in Units, $ in Thousands	12 Months Ended
	Dec. 31, 2021 USD ($) $ / shares shares
Schedule of unaudited pro forma combined financial information [Abstract]
Net loss \| $	$ (33,754)
Pro forma loss per common share, basic and diluted \| $ / shares	$ (4.62)
Pro forma weighted average number of common shares outstanding, basic and diluted \| shares	7,304,201

Fair Value of Financial Instruments (Details) - Schedule of financial instruments measured at fair value on a recurring basis $ in Thousands	Dec. 31, 2021 USD ($)
Cash Equivalents
Money market funds	$ 26,323
Marketable debt securities
Total	122,040
Money Market Funds Non-Current [Member]
Restricted cash, non-current
Money market funds	745
Corporate Bonds [Member]
Marketable debt securities
Corporate bonds	94,972
Level 1 [Member]
Cash Equivalents
Money market funds	26,323
Marketable debt securities
Total	27,068
Level 1 [Member] \| Money Market Funds Non-Current [Member]
Restricted cash, non-current
Money market funds	745
Level 1 [Member] \| Corporate Bonds [Member]
Marketable debt securities
Corporate bonds
Level 2 [Member]
Cash Equivalents
Money market funds
Marketable debt securities
Total	94,972
Level 2 [Member] \| Money Market Funds Non-Current [Member]
Restricted cash, non-current
Money market funds
Level 2 [Member] \| Corporate Bonds [Member]
Marketable debt securities
Corporate bonds	94,972
Level 3 [Member]
Cash Equivalents
Money market funds
Marketable debt securities
Total
Level 3 [Member] \| Money Market Funds Non-Current [Member]
Restricted cash, non-current
Money market funds
Level 3 [Member] \| Corporate Bonds [Member]
Marketable debt securities
Corporate bonds

Marketable Debt Securities (Details) - Schedule of marketable debt securities $ in Thousands	Dec. 31, 2021 USD ($)
Marketable Securities [Line Items]
Amortized Cost	$ 95,183
Unrealized Gains
Unrealized Losses	(211)
Estimated Fair Value	94,972
Corporate Bonds - presented in marketable debt securities, current [Member]
Marketable Securities [Line Items]
Amortized Cost	55,548
Unrealized Gains
Unrealized Losses	(43)
Estimated Fair Value	55,505
Corporate Bonds - presented in marketable debt securities, non-current [Member]
Marketable Securities [Line Items]
Amortized Cost	39,635
Unrealized Gains
Unrealized Losses	(168)
Estimated Fair Value	$ 39,467

Marketable Debt Securities (Details) - Schedule of investment income - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Schedule of investment income [Abstract]
Interest income	$ 1,974	$ 500
Accretion/(amortization) of discount/premium, net	(1,737)
Total interest and investment income	$ 237	$ 500

Prepaid Expenses and Other Current Assets (Details) - Schedule of prepaid expenses and other current assets - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Schedule of prepaid expenses and other current assets [Abstract]
Prepaid insurance	$ 279	$ 292
Prepaid research and development	684	209
Prepaid software	79	10
Accrued interest on marketable debt securities	634
Prepaid rent		113
Other prepaid expenses	173	111
Other current assets	34	52
Total	$ 1,883	$ 787

Property and Equipment, net (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Property and Equipment, net (Details) [Line Items]
Depreciation expense	$ 117	$ 103
Total property and equipment, net	100.00%	100.00%
Research and Development Expense [Member]
Property and Equipment, net (Details) [Line Items]
Depreciation expense	$ 36	$ 99
General and Administrative Expense [Member]
Property and Equipment, net (Details) [Line Items]
Depreciation expense	$ 81	$ 4

Property and Equipment, net (Details) - Schedule of property and equipment consists - USD ($) $ in Thousands	Dec. 31, 2021	Dec. 31, 2020
Property, Plant and Equipment [Line Items]
Total property and equipment, gross	$ 1,955	$ 1,359
Property and equipment not yet placed into service	613	503
Less: Accumulated depreciation	(236)	(119)
Total property and equipment, net	1,719	1,240
Computer Equipment [Member]
Property, Plant and Equipment [Line Items]
Total property and equipment, gross	175	34
Furniture, Fixtures And Other [Member]
Property, Plant and Equipment [Line Items]
Total property and equipment, gross	352	21
Laboratory Equipment [Member]
Property, Plant and Equipment [Line Items]
Total property and equipment, gross	591	601
Leasehold Improvements [Member]
Property, Plant and Equipment [Line Items]
Total property and equipment, gross	$ 224	$ 200

Accrued Expenses (Details) - Schedule of accrued expenses - USD ($) $ in Thousands	Dec. 31, 2021	Dec. 31, 2020
Schedule of accrued expenses [Abstract]
Payroll	$ 1,801	$ 1,530
Taxes	41	159
Legal fees	29	156
Research and development costs	437	37
Other expenses	181	31
Total	$ 2,489	$ 1,913

Short-Term Debt (Details) - USD ($) $ in Thousands	1 Months Ended	12 Months Ended
Short-Term Debt (Details) - USD ($) $ in Thousands	Feb. 19, 2020	Dec. 31, 2021	Dec. 31, 2020
Debt Disclosure [Abstract]
Description of financing agreement	the Company entered into a nine-month financing agreement with AFCO Credit Corporation for its directors and officers (“D&O”) liability insurance in the amount of $2,225. The Company made a down payment of $556, leaving a principal balance of $1,669. The financing bore interest at a rate of 4.25% per annum, and was repaid in monthly installments of $189, which included both principal and interest.
Debt amount		$ 0	$ 0
Interest expense		$ 0	$ 34

Leases (Details) - USD ($) $ in Thousands	12 Months Ended
Leases (Details) - USD ($) $ in Thousands	Dec. 31, 2021	Dec. 31, 2020
Leases [Abstract]
Lease description		the Company entered into an agreement to lease approximately 10.3 square feet of office space in New York, New York (“Office Lease”), which commenced in April 2021. The office space is owned by an affiliate of Deerfield Management Company, L.P., which together with its affiliates beneficially owned more than 5% of the Company’s voting securities at the time the lease was executed. Annual rent is approximately $1,117.
Restricted cash	$ 745	$ 745
Operating leases	1,009	$ 66
Right of use asset obtained in exchange for operating lease liabilities	$ 6,549

Leases (Details) - Schedule of lease cost - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Schedule of lease cost [Abstract]
Operating lease expense	$ 1,050	$ 93
Short-term lease expense	102	215
Total	$ 1,152	$ 308

Leases (Details) - Schedule of other information related to leases	Dec. 31, 2021	Dec. 31, 2020
Schedule of other information related to leases [Abstract]
Weighted-average discount rate	7.00%	12.00%
Weighted-average remaining lease term – operating lease (in months)	79 months	87 months

Leases (Details) - Schedule of annual minimum lease payments of operating lease liabilities $ in Thousands	Dec. 31, 2021 USD ($)
Schedule of annual minimum lease payments of operating lease liabilities [Abstract]
2022	$ 1,327
2023	1,327
2024	1,327
2025	1,395
2026	1,429
Thereafter	2,234
Total gross operating lease payments	9,039
Less: imputed interest	(1,800)
Total lease liabilities, reflecting present value of future minimum lease payments	$ 7,239

Commitments and Contingencies (Details) - USD ($) $ in Thousands	1 Months Ended			12 Months Ended
	Nov. 28, 2018	Dec. 22, 2017	Sep. 27, 2017	Dec. 31, 2021	Dec. 31, 2020
License Agreement [Member]
Commitments and Contingencies (Details) [Line Items]
Description of license agreement		the Company entered into an agreement (the “Feinstein Agreement”) with The Feinstein Institute for Medical Research (the “Feinstein Institute”), a not-for-profit corporation with 50 research labs and 2,500 clinical research studies. Pursuant to the Feinstein Agreement, the Company acquired an exclusive license relating to treatment of fatty liver diseases in humans for which Choline may be an effective therapeutic. In consideration for the rights and license granted, the Feinstein Institute would receive a royalty of one percent (1%) of the first one hundred million dollars ($100,000) of net sales of IV Choline Chloride and a royalty of one and one-half percent (1.5%) of all net sales thereafter. In addition, the Company would pay the Feinstein Institute twelve and one-half percent (12.5%) of net proceeds resulting from agreements entered within 2 years from the effective date, and seven and one-half percent (7.5%) of net proceeds resulting from agreements entered into thereafter. Pursuant to the Feinstein Agreement additional payments would be due to the Feinstein Institute for license maintenance payments and for meeting milestone events. Pursuant to the Feinstein Agreement, upon the achievement of certain future new drug application milestones, the Company would be obligated to remit an aggregate of $275.
Choline License Agreement [Member]
Commitments and Contingencies (Details) [Line Items]
Description of choline license agreement			the Company entered into a license agreement (the “Choline License Agreement”) with Alan L. Buchman (“Dr. Buchman”). Pursuant to the Choline License Agreement, the Company received from Dr. Buchman the license rights in and to the “Licensed Orphan Designations”, the “Licensed IND”, “Existing Study Data” and the “Licensed Know-How” for one or more of the licensed indications.
Feinstein Agreement [Member]
Commitments and Contingencies (Details) [Line Items]
Research and development expense				$ 15	$ 115
Sponsored Research and License Agreement [Member]
Commitments and Contingencies (Details) [Line Items]
Description of sponsored research and license agreement	the Company entered into a sponsored research and license agreement (the “Iowa Agreement”) with the University of Iowa. Pursuant to the Iowa Agreement, the University of Iowa, which is engaged in clinical research to improve the diagnosis and treatment of lymphangioma using a pharmaceutical product (OK-432), would assist the Company in collecting case reports, forms, source data, and safety data available to the University of Iowa in support of the development of the Company’s proprietary Streptococcus Pyogenes investigational product, TARA-002 for the LMs indication. During the term of the services, the Company would generally pay the University of Iowa thirty thousand dollars ($30) per year to fund the project, plus additional amounts upon the realization of certain milestones. More specifically, upon forty-five (45) days of an approval of TARA-002 by the FDA, the Company would pay up to $1,750 to the University of Iowa for meeting these milestones. Furthermore, the Company would pay the University of Iowa royalties of up to 1.75% for net sales ranging from $0 - $25,000, 2.25% for net sales ranging from $25,000 to $50,000, and 2.50% for net sales in excess of $50,000. Pursuant to the Iowa Agreement, the University of Iowa would be entitled to additional payments for the Company achieving annual net sales of product according to the milestones. For annual net sales of product up to $25,000; $62; for annual net sales of product of up to $50,000; $62; and for annual net sales of product of up to $100,000; $125.
Lowa Agreement [Member]
Commitments and Contingencies (Details) [Line Items]
Research and development expense				$ 0	$ 30

Stockholders’ Equity (Details) - USD ($) $ / shares in Units, $ in Thousands		1 Months Ended	12 Months Ended
	Oct. 06, 2020	Sep. 24, 2020	Dec. 31, 2021	Dec. 31, 2020	Sep. 22, 2020
Stockholders’ Equity (Details) [Line Items]
Common stock authorized			100,000,000	100,000,000
Common shares of par value (in Dollars per share)			$ 0.001	$ 0.001
Common stock shares issued			11,235,731	11,211,840
Common stock, shares outstanding			11,235,731	11,211,840
Preferred stock, shares authorized			10,000,000	10,000,000
Preferred shares of par value (in Dollars per share)			$ 0.001	$ 0.001
Common stock issuance and outstanding, percentage			9.99%
Proceeds from Issuance of Common Stock (in Dollars)				$ 73,570
Underwritten Public Offering [Member]
Stockholders’ Equity (Details) [Line Items]
Aggregate of shares of common stock		4,600,000
Offering price, per share (in Dollars per share)		$ 16.87
Proceeds from Issuance of Common Stock (in Dollars)		$ 77,600
Net proceeds (in Dollars)		$ 73,600
Granted option to purchase		690,000
Over-Allotment Option [Member]
Stockholders’ Equity (Details) [Line Items]
Net proceeds (in Dollars)	$ 11,100
Granted option to purchase	690,000
Gross proceeds (in Dollars)	$ 11,600
Common Stock [Member]
Stockholders’ Equity (Details) [Line Items]
Common stock authorized			100,000,000
Common shares of par value (in Dollars per share)			$ 0.001
Common stock shares issued			11,235,731	11,211,840
Common stock, shares outstanding			11,235,731	11,211,840
Series 1 Convertible Preferred Stock [Member]
Stockholders’ Equity (Details) [Line Items]
Preferred stock, shares issued			8,027
Preferred stock, shares authorized			8,028
Preferred stock, shares outstanding				8,027
Conversion of stock shares			1,000
Conversion price per share (in Dollars per share)			$ 7.01
Convertible preferred stock, percentage			19.99%
Preferred stock is convertible into share of common stock			10
Series 1 Convertible Preferred Stock [Member] \| Minimum [Member]
Stockholders’ Equity (Details) [Line Items]
Preferred stock, shares issued					3,880
Series 1 Convertible Preferred Stock [Member] \| Maximum [Member]
Stockholders’ Equity (Details) [Line Items]
Preferred stock, shares issued					8,028
Series 1 Convertible Preferred Stock [Member] \| Underwritten Public Offering [Member]
Stockholders’ Equity (Details) [Line Items]
Aggregate of shares of common stock		4,148
Offering price, per share (in Dollars per share)		$ 16,873.54
Net proceeds (in Dollars)		$ 66,300
Gross proceeds (in Dollars)		$ 70,000

Stock-Based Compensation (Details) - USD ($) $ / shares in Units, $ in Thousands	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Jan. 01, 2022	Jan. 01, 2021	Jan. 01, 2020	Aug. 10, 2017	Oct. 03, 2014
Stock-Based Compensation (Details) [Line Items]
Issuance of common stock	600,000
Shares available for issuance	20,365
Common stock, shares authorized	100,000,000	100,000,000
Common stock, shares issued	11,235,731	11,211,840
Intrinsic value options exercised (in Dollars)		$ 696
Weighted average grant date fair value per share (in Dollars per share)	$ 12.6	$ 22.61
Unrecognized share-based compensation (in Dollars)	$ 12,664
Weighted average period term	2 years 8 months 15 days
Restricted Stock Units (RSUs) [Member]
Stock-Based Compensation (Details) [Line Items]
Unamortized value of RSUs (in Dollars)	$ 1,835
Weighted average remaining amortization period	2 years 4 months 20 days
Number of RSUs	286,918	132,709
Common stock, shares issued	23,891
Net settlement (in Dollars)	$ 34,706
Net share settlement (in Dollars)	$ 228
Weighted average grant date fair value per share (in Dollars per share)	$ 29.46
2020 Inducement Plan [Member]
Stock-Based Compensation (Details) [Line Items]
Shares available for issuance	420,500
2017 Equity Incentive Plan [Member]
Stock-Based Compensation (Details) [Line Items]
Shares available for issuance						2,000,000
Twenty Fourteen Equity Incentive Plan [Member]
Stock-Based Compensation (Details) [Line Items]
Shares available for issuance	398,604				1,048,300
Twenty Fourteen Equity Incentive Plan [Member] \| Minimum [Member]
Stock-Based Compensation (Details) [Line Items]
Common stock, shares authorized				812,889
Twenty Fourteen Equity Incentive Plan [Member] \| Minimum [Member] \| Subsequent Event [Member]
Stock-Based Compensation (Details) [Line Items]
Common stock, shares authorized			840,181
Twenty Fourteen Equity Incentive Plan [Member] \| Maximum [Member]
Stock-Based Compensation (Details) [Line Items]
Common stock, shares authorized				1,861,189
Twenty Fourteen Equity Incentive Plan [Member] \| Maximum [Member] \| Subsequent Event [Member]
Stock-Based Compensation (Details) [Line Items]
Shares available for issuance			1,238,785
2014 Employee Stock Purchase Plan [Member]
Stock-Based Compensation (Details) [Line Items]
Common stock, shares authorized							3,513
Number of shares authorized	25,037
2014 Employee Stock Purchase Plan [Member] \| Minimum [Member]
Stock-Based Compensation (Details) [Line Items]
Number of share authorized increased				7,025
2014 Employee Stock Purchase Plan [Member] \| Minimum [Member] \| Subsequent Event [Member]
Stock-Based Compensation (Details) [Line Items]
Common stock, shares authorized			7,025
2014 Employee Stock Purchase Plan [Member] \| Maximum [Member]
Stock-Based Compensation (Details) [Line Items]
Number of share authorized increased				25,037
2014 Employee Stock Purchase Plan [Member] \| Maximum [Member] \| Subsequent Event [Member]
Stock-Based Compensation (Details) [Line Items]
Shares available for issuance			32,062
Board of Directors [Member] \| 2014 Employee Stock Purchase Plan [Member] \| Minimum [Member]
Stock-Based Compensation (Details) [Line Items]
Common stock, shares authorized							7,025

Stock-Based Compensation (Details) - Schedule of restricted stock unit activities - Restricted stock unit [Member]	12 Months Ended
	Dec. 31, 2021 $ / shares shares
Stock-Based Compensation (Details) - Schedule of restricted stock unit activities [Line Items]
Restricted Stock Units, Balance at beginning \| shares	274,616
Weighted Average Grant Date Fair Value, Balance at beginning \| $ / shares	$ 29.95
Restricted Stock Units, Granted \| shares	10,500
Weighted Average Grant Date Fair Value, Granted \| $ / shares	$ 11.16
Restricted Stock Units, Forfeited \| shares
Weighted Average Grant Date Fair Value, Forfeited \| $ / shares
Restricted Stock Units, Vested \| shares	(188,915)
Weighted Average Grant Date Fair Value, Vested \| $ / shares	$ 29.46
Restricted Stock Units, Balance at ending \| shares	96,201
Weighted Average Grant Date Fair Value, Balance at ending \| $ / shares	$ 28.87

Stock-Based Compensation (Details) - Schedule of the fair value of stock options granted - $ / shares	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Stock-Based Compensation (Details) - Schedule of the fair value of stock options granted [Line Items]
Dividend yield	0.00%	0.00%
Minimum [Member]
Stock-Based Compensation (Details) - Schedule of the fair value of stock options granted [Line Items]
Exercise price (in Dollars per share)	$ 6.56	$ 17.84
Expected volatility	89.00%	95.00%
Risk-free interest rate	0.45%	0.28%
Expected life (in years)	5 years 3 months 7 days	5 years 3 months 7 days
Maximum [Member]
Stock-Based Compensation (Details) - Schedule of the fair value of stock options granted [Line Items]
Exercise price (in Dollars per share)	$ 19.82	$ 51.12
Expected volatility	98.00%	101.00%
Risk-free interest rate	1.33%	1.69%
Expected life (in years)	6 years 29 days	6 years 29 days

Stock-Based Compensation (Details) - Schedule of stock option activities - Equity Option [Member]
$ / shares in Units, $ in Thousands

12 Months Ended

Dec. 31, 2021

USD ($)

$ / shares

Stock-Based Compensation (Details) - Schedule of stock option activities [Line Items]

Number of Options, Balance at beginning | shares

674,039

Weighted Average Exercise Price, Balance at beginning | $ / shares

$ 25.23

Weighted Average Remaining Contractual Term (years), Balance at beginning

9 years 21 days

Options, Aggregate Intrinsic Value, Balance at beginning | $

$ 2,311

^[1]

Number of Options, Balance at ending | shares

1,356,639

Weighted Average Exercise Price, Balance at ending | $ / shares

$ 20.51

Weighted Average Remaining Contractual Term (years), Balance at ending

8 years 7 months 2 days

Aggregate Intrinsic Value, Balance at ending | $

$ 1

^[1]

Number of Options, Vested or expected to vest | shares

1,356,639

Weighted Average Exercise Price, Vested or expected to vest | $ / shares

$ 20.51

Weighted Average Remaining Contractual Term (years), Vested or expected to vest

8 years 7 months 2 days

Aggregate Intrinsic Value, Vested or expected to vest | $

^[1]

Number of Options, Exercisable | shares

407,981

Weighted Average Exercise Price, Exercisable | $ / shares

$ 21.97

Weighted Average Remaining Contractual Term (years), Exercisable

7 years 9 months 29 days

Aggregate Intrinsic Value, Exercisable | $

^[1]

Number of Options, Granted | shares

861,850

Weighted Average Exercise Price, Granted | $ / shares

$ 16.32

Weighted Average Remaining Contractual Term (years), Granted

Aggregate Intrinsic Value, Granted | $

^[1]

Number of Options, Exercised | shares

Weighted Average Exercise Price, Exercised | $ / shares

Weighted Average Remaining Contractual Term (years), Exercised

Aggregate Intrinsic Value, Exercised | $

^[1]

Number of Options, Forfeited | shares

(168,196)

Weighted Average Exercise Price, Forfeited | $ / shares

$ 17.62

Weighted Average Remaining Contractual Term (years), Forfeited

Aggregate Intrinsic Value, Forfeited | $

^[1]

Number of Options, Expired | shares

(11,054)

Weighted Average Exercise Price, Expired | $ / shares

$ 26.15

Weighted Average Remaining Contractual Term (years),Expired

Aggregate Intrinsic Value, Expired | $

^[1]

[1]

Stock-Based Compensation (Details) - Schedule of total stock-based compensation costs - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Stock-Based Compensation (Details) - Schedule of total stock-based compensation costs [Line Items]
Total stock-based compensation	$ 10,362	$ 9,746
RSUs [Member]
Stock-Based Compensation (Details) - Schedule of total stock-based compensation costs [Line Items]
Total stock-based compensation	4,520	6,357
Stock options [Member]
Stock-Based Compensation (Details) - Schedule of total stock-based compensation costs [Line Items]
Total stock-based compensation	$ 5,842	$ 3,389

Stock-Based Compensation (Details) - Schedule of stock-based compensation expense - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Total stock-based compensation	$ 10,362	$ 9,746
Research and development [Member]
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Total stock-based compensation	1,409	741
General and administrative [Member]
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Total stock-based compensation	$ 8,953	$ 9,005

Income Taxes (Details) - USD ($) $ in Millions	12 Months Ended
Income Taxes (Details) - USD ($) $ in Millions	Dec. 31, 2021	Dec. 31, 2020
Income Taxes (Details) [Line Items]
Effective tax rate description		For the year ended December 31, 2021, the Company’s effective tax rate was 0%, which consisted principally of a federal rate of 21%, and the Company’s estimate of state taxes, net of federal benefit, of 0.6%, offset by a valuation allowance 12.9% and true-up to the prior years tax return of 8.2%.
Carried forward tax year	20 years
Carried forward tax	$ 99.6
Valuation allowance	27.8	$ 21.7
Federal NOL [Member]
Income Taxes (Details) [Line Items]
Carried forward tax	0.6
U.S. federal [Member]
Income Taxes (Details) [Line Items]
Net operating losses	100.2
State income tax [Member]
Income Taxes (Details) [Line Items]
Net operating losses	$ 29.6

Income Taxes (Details) - Schedule of federal and state income tax expense - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Current
Federal
State
Total current
Deferred
Federal	(8,918)	(6,211)
State	4,294	(2,439)
Total deferred	(4,624)	(8,650)
Change in valuation allowance	4,624	8,650
Total income tax expense (benefit)

Income Taxes (Details) - Schedule of deferred tax assets and liabilities - USD ($) $ in Thousands	Dec. 31, 2021	Dec. 31, 2020
Deferred tax assets:
Net operating loss carry forwards	$ 23,350	$ 19,371
Stock option expense	920	443
Research and development credits	1,551	70
Operating lease liability	1,564	330
RSU expense	1,960	1,796
Other	7	10
Total deferred tax assets	29,352	22,020
Valuation allowance	(27,803)	(21,698)
Deferred tax assets, net of valuation allowance	1,549	322
Deferred tax liabilities:
Operating right-of-use asset	(1,549)	(322)
Total deferred tax liabilities	(1,549)	(322)
Deferred tax assets, net of valuation allowance and deferred tax liabilities

Income Taxes (Details) - Schedule of federal income tax to income before provision for income taxes	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Schedule of federal income tax to income before provision for income taxes [Abstract]
U.S. federal statutory rate	(21.00%)	(21.00%)
State taxes, net of federal benefit	(0.60%)	(9.40%)
Research and development credits	(3.30%)
Option expense	1.10%	1.20%
Other	1.20%	1.90%
True-up to prior years return	8.20%	1.80%
State rate change	1.50%
Change in valuation allowance	12.90%	25.50%
Effective tax rate

Employee Benefit Plan (Details)	12 Months Ended
Employee Benefit Plan (Details)	Dec. 31, 2021
Retirement Benefits [Abstract]
Defined contribution benefit plan, description	The Company maintains a defined contribution benefit plan under section 401(k) of the Internal Revenue Code covering substantially all qualified employees of the Company (the “401(k) Plan”). Under the 401(k) Plan, the Company matches 100% up to a 4% contribution. The 401(k) Plan was implemented in June of 2020. For the years ended December 31, 2021 and 2020, the Company recorded expense of $215 and $69, respectively, representing employer contributions under the 401(k) Plan.

Net Loss Per Common Share (Details) - Schedule of net loss per share attributable to common stockholders, basic and diluted - USD ($) $ / shares in Units, $ in Thousands	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Numerator:
Net loss attributable to common stockholders	$ 47,252	$ 33,978
Denominator:
Weighted-average common shares outstanding – basic and diluted	11,232,576	7,233,913
Net loss per share attributable to common stockholders, basic and diluted	$ (4.21)	$ (4.7)

- Definition

Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities; of income (loss) available to common shareholders.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=124431687&loc=d3e22595-107794

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 10
-URI http://asc.fasb.org/extlink&oid=125511455&loc=d3e1448-109256

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 11
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 11
-URI http://asc.fasb.org/extlink&oid=125511455&loc=d3e1377-109256

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 22
-URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 11
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 60B
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=125511455&loc=SL5780133-109256

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (f)
-URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599

Reference 10: http://www.xbrl.org/2003/role/exampleRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 31
-URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8924-108599

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 30
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=124431687&loc=d3e22583-107794

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599

+ Details

Net Loss Per Common Share (Details) - Schedule of weighted average dilutive common shares - shares	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Schedule of weighted average dilutive common shares [Abstract]
Stock options issued and outstanding	1,356,639	674,039
Restricted stock units issued and outstanding	383,119	407,325
Conversion of Series 1 Convertible Preferred Stock	8,029,039	8,029,039
Total potentially dilutive shares	9,768,797	9,110,403